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Abstract: Background 
Thyroid eye disease is a disabling inflammatory orbital condition which 
causes visual dysfunction and psychological morbidity. Standard treatment 
is with systemic corticosteroids, but the additional benefit of orbital 
radiotherapy and antiproliferative immunosuppression is unclear.  
 
Methods  
Participants all received a  24 week course of oral prednisolone and were 
also randomised to receive radiotherapy or sham-radiotherapy, and 
azathioprine or placebo, in a 2x2 factorial design. The primary outcomes 
were a binary composite clinical outcome score and ophthalmopathy index 
at 48 weeks and clinical activity score at 12 weeks. (ISRCTN 22471573).  
 
Findings 
126 adults with active moderate-to-severe thyroid eye disease were 
randomised. 103 provided outcome data, of which 84 completed their 
allocated treatment of  radiotherapy or sham-radiotherapy, and 57 
continued to take azathioprine or placebo until 48 weeks. Pre-specified 
intention-to-treat analysis of the binary clinical composite outcome 
measure revealed an odds of improvement for azathioprine of OR(adj)=2·56 
(95%CI 0·98, 6·66; p=0·05) and for radiotherapy of OR(adj)=0·89 (95%CI 
0·36, 2·23; p=0·80). In a post-hoc analysis of patients completing their 
allocated therapy, improvement was more frequent on azathioprine 
(OR(adj)=6·83; 95%CI 1·66, 28.1; p=0·008 than radiotherapy (OR(adj)=0·71; 
95%CI 0·26, 1·95; p=0·50).  The ophthalmopathy index, clinical activity 
score and number of adverse events (azathioprine N=161, radiotherapy 
N=156) did not differ between treatment groups. 
 
Interpretation  
In patients receiving oral prednisolone for 24 weeks, the addition of 
radiotherapy was not beneficial. With regard to azathioprine, our 
conclusions are limited by a high number of withdrawals from treatment. 
However, these results suggest that disease severity at 48 weeks was 
reduced in participants who completed azathioprine treatment. 
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Abstract 53 
Background 54 
Thyroid eye disease is a disabling inflammatory orbital condition which causes visual 55 
dysfunction and psychological morbidity. Standard treatment is with systemic corticosteroids, 56 
but the additional benefit of orbital radiotherapy and antiproliferative immunosuppression is 57 
unclear.  58 
 59 
Methods  60 
Participants all received a  24 week course of oral prednisolone and were also randomised to 61 
receive radiotherapy or sham-radiotherapy, and azathioprine or placebo, in a 2x2 factorial 62 
design. The primary outcomes were a binary composite clinical outcome score and 63 
ophthalmopathy index at 48 weeks and clinical activity score at 12 weeks. (ISRCTN 64 
22471573).   65 
 66 
Findings 67 
126 adults with active moderate-to-severe thyroid eye disease were randomised. 103 68 
provided outcome data, of which 84 completed their allocated treatment of  radiotherapy or 69 
sham-radiotherapy, and 57 continued to take azathioprine or placebo until 48 weeks. Pre-70 
specified intention-to-treat analysis of the binary clinical composite outcome measure 71 
revealed an odds of improvement for azathioprine of OR(adj)=2·56 (95%CI 0·98, 6·66; 72 
p=0·05) and for radiotherapy of OR(adj)=0·89 (95%CI 0·36, 2·23; p=0·80). In a post-hoc 73 
analysis of patients completing their allocated therapy, improvement was more frequent on 74 
azathioprine (OR(adj)=6·83; 95%CI 1·66, 28.1; p=0·008 than radiotherapy (OR(adj)=0·71; 75 
95%CI 0·26, 1·95; p=0·50).  The ophthalmopathy index, clinical activity score and number 76 
of adverse events (azathioprine N=161, radiotherapy N=156) did not differ between treatment 77 
groups. 78 
 79 
Interpretation  80 
In patients receiving oral prednisolone for 24 weeks, the addition of radiotherapy was not 81 
beneficial. With regard to azathioprine, our conclusions are limited by a high number of 82 
withdrawals from treatment. However, these results suggest that disease severity at 48 weeks 83 
was reduced in participants who completed azathioprine treatment. 84 
  85 
Funding 86 
National Eye Research Centre, Above and Beyond and Moorfields Eye Charity, supported by 87 
infrastructural investment from the National Institute for Health Research  88 
 89 
  90 
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  91 Research in Context 
 Active moderate-to-severe thyroid eye disease is currently treated with systemic corticosteroids, but 
outcomes are often sub-optimal. Corticosteroids are most effective when administered intravenously, 
but this is inconvenient, and oral administration remains common in global clinical practice. 
However, uncertainty remains about the additional benefit of orbital radiotherapy and antiproliferative 
immunosuppressive drugs.  
 
Evidence before this study 
Previous retrospective case series have reported that the antiproliferative immunosuppressive drug 
azathioprine reduces disease severity and the need for rehabilitative surgery, but no prior RCTs have 
been completed. The evidence base for orbital radiotherapy is stronger, but conflicting, especially in 
the context of systemic corticosteroid treatment.  
 
Added value of this study 
Eighty per cent of subjects completed radiotherapy, but no significant short (12 week) or long-term 
(48 week) benefit resulted over and above the improvement seen with a 24-week tapering course of 
oral corticosteroids.  Less strong conclusions can be drawn with regard to azathioprine, as many 
patients did not complete treatment due to abnormalities in monitoring blood tests or side-effects, but 
those that continued azathioprine for more than 24 weeks benefitted, predominantly due to a 
prevention of deterioration after the end of corticosteroid treatment.  
 
Implications of all the available evidence 
These results do not support the use of radiotherapy in thyroid eye disease in patients also treated with 
systemic corticosteroids. They also provide evidence in favour of the use of anti-proliferative 
immunosuppressive agents such as azathioprine beyond the period of corticosteroid therapy to 
improve long-term clinical outcomes. 
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Introduction 92 
Active moderate-to-severe thyroid eye disease, also known as Graves’ orbitopathy or thyroid 93 
associated orbitopathy) occurs in 5-10% of cases of Graves’ disease(1). It can be both 94 
visually disabling and cosmetically disfiguring and substantially impairs quality of life(1-3). 95 
The aim of treatment is to suppress orbital inflammation and reduce consequent tissue re-96 
modelling in extraocular muscles, orbital fat and other periocular soft tissues(4, 5). 97 
Immunosuppressive therapies, in particular corticosteroids(1, 4, 6), are the mainstay of 98 
treatment for active moderate-to-severe thyroid eye disease (1). However, they are typically 99 
withdrawn after 24 weeks of treatment to limit cumulative toxicity regardless of whether they 100 
are administered via the oral or intravenous route(7), and given that active disease lasts 1–2 101 
years, recurrence at the time of withdrawal often occurs(1, 7-9).   102 
 103 
Consequently, the avoidance of corticosteroid side-effects, improvement in treatment efficacy 104 
and maintenance of long-term disease control are major goals for the field of thyroid eye 105 
disease as a whole. However, efforts to use monoclonal antibody therapies to more 106 
selectively suppress disease are still either early in their route to market(10), or have failed to 107 
demonstrate definitive treatment benefit(11, 12). Hence, given the proven short-term efficacy 108 
of corticosteroids in the treatment of active moderate-to-severe thyroid eye disease, it is 109 
likely that they will remain the gold-standard first-line treatment for several years to come, 110 
and the need to find adjunctive therapies to augment and sustain their benefit remains very 111 
real. 112 
 113 
To date, the only non-corticosteroid conventional immunosuppressant drug to have been 114 
evaluated in RCTs is cyclosporine A(13, 14), which was found to be beneficial, but its use 115 
has not been widely adopted because of concerns about side-effects(6). An alternative 116 
strategy is to use an antiproliferative agent such as azathioprine as it is better tolerated than 117 
cyclosporine A(15, 16) and although ineffective as monotherapy(17), retrospective data 118 
indicates that in combination with corticosteroids it reduces disease severity and the need for 119 
rehabilitative surgery(18).  In addition to immunosuppression, non-pharmaceutical treatment 120 
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of active thyroid eye disease  with orbital radiotherapy has been advocated for decades, and 121 
older RCTs demonstrated that this was more effective when used in combination with 122 
corticosteroids(19, 20). However, subsequent studies either questioned the role of orbital 123 
radiotherapy or concluded that its benefit was limited to improvement in oculomotility(21-124 
23). This has generated significant controversy, in particular due to concerns about the entry 125 
criteria, trial design and radiotherapy administration in Gorman et al’s paper(22), which has 126 
led to disparity in practice. Orbital radiotherapy has now been largely abandoned in North 127 
America, whereas in European centres, including the UK, it is still routinely used(6, 23-25).  128 
As it is administered daily over 2-3 weeks and patients are typically of working age, this also 129 
has significant implications for the use of healthcare resources and patients’ time. 130 
Furthermore, only two relatively small studies have evaluated the additional effect of 131 
radiotherapy when combined with a high-dose course of systemic corticosteroids(19, 20), and 132 
clinical outcomes beyond 24 weeks have rarely been reported for any intervention in thyroid 133 
eye disease. We therefore sought to evaluate the long-term benefit of orbital radiotherapy and 134 
antiproliferative immunosuppression with azathioprine in the context of sustained systemic 135 
corticosteroid treatment for active moderate-to-severe thyroid eye disease . 136 
 137 
Methods 138 
Study design and participants 139 
We undertook this factorial design multicentre RCT in 6 centres in the UK. Patients  aged 20-140 
75 years were recruited to receive either azathioprine or placebo, plus either orbital 141 
radiotherapy or sham-radiotherapy, in combination with a standardised 24-week tapering oral 142 
prednisolone regime (Supplementary Table 1 and Supplementary Figure 1). In brief, all 143 
patients received an initial oral prednisolone dose of 80mg / day, which reduced to 20mg / 144 
day by 6 weeks, 10mg / day by 15 weeks and 5mg / day by 21 weeks. In accordance with the 145 
factorial design, study recruits were then randomly allocated into 4 groups 2 weeks after 146 
starting corticosteroids: azathioprine plus orbital radiotherapy, azathioprine plus sham-147 
radiotherapy, placebo plus orbital radiotherapy, or placebo plus sham-radiotherapy.  Full 148 
protocol details, including pre-specified primary and secondary outcome measures and 149 
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statistical analyses, have been previously peer-reviewed, published and are openly 150 
available(26). Trial registration was assigned retrospectively on 1 February 2006 151 
(ISRCTN22471573) following regulatory permissions, but prior to starting recruitment. 152 
 153 
Eligible patients had  a clinical activity score(27) ≥ 4 (worst eye) OR ≥ 2 (worst eye) with a 154 
history of proptosis or motility restriction of less than 6 months duration. They were also 155 
required to have a past or present history of abnormal thyroid function or a clinical diagnosis 156 
of thyroid eye disease made and confirmed by ≥2 muscle involvement on computed 157 
tomography or magnetic resonance imaging scan. The clinical activity score was scored out 158 
of 7 at the enrolment visit as its last 3 items (decreasing proptosis, decreasing visual acuity 159 
and decreasing eye movement) require a change in consecutive measurements to be 160 
calculated. This therefore cannot be done at the first assessment, but at all subsequent visits 161 
clinical activity score was scored out of 10.  If study recruits either had a < 6 month history 162 
of thyroid eye disease (defined as time since first symptom) or an improvement in any item 163 
of clinical activity score 2 weeks after starting the trial prednisolone regime, they were 164 
considered to have active disease and were randomised at the second trial visit. Key 165 
exclusion criteria included age <20 or >75 years, dysthyroid optic neuropathy, abnormal 166 
thiopurine methyltransferase activity and use of radioiodine or any immunomodulatory or 167 
cytotoxic drugs within the last 3 months (thyroidectomy was permitted).  168 
 169 
Randomisation and masking 170 
Patients’ eligibility for the study was assessed by the ophthalmic investigators at each trial 171 
centre. Allocation to treatment groups was by remote computerised randomisation and 172 
minimisation was used to reduce baseline disparities in potential confounding variables 173 
between trial interventions. These included smoking status at the time of thyroid eye disease 174 
diagnosis, thyroid status on enrolment, previous corticosteroid use, gender, disease 175 
severity, study centre, disease duration, age greater than 60 years and disease activity.  176 
Patients, clinicians (both ophthalmic and endocrine) and data analysts were all masked. Only 177 
the trial co-ordinators (who monitored trial subjects blood results), pharmacists and 178 
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radiographers were unmasked. The success of masking for ophthalmic investigators and 179 
patients was assessed at study completion or withdrawal by asking them to declare which 180 
treatments they thought had been administered.  181 
 182 
Procedures 183 
Orbital radiotherapy 184 
Twenty gray (Gy) of radiation was administered to the retrobulbar orbit in 10-12 fractions 185 
over 2 to 3 weeks. Subjects receiving sham-radiotherapy also attended and underwent all the 186 
same procedures other than no radiation being delivered. Extensive effort was used across 187 
trial centres to ensure participants were unable to identify if they were receiving sham 188 
therapy, including use of a noise emitting device to simulate treatment administration(26) (for 189 
details of the radiotherapy procedures at each trial centre see Supplementary Text 2) 190 
 191 
Azathioprine 192 
Treatment dose varied between 100mg and 200mg daily (dispensed as 50 mg tablets), 193 
depending on body weight. Matched placebo tablets and packaging were used and the dose 194 
was adjusted according to a standard algorithm dependent on patients’ blood test results. 195 
Again, extensive effort was taken to ensure participants were unaware if they were receiving 196 
placebo, including identical blood tests and random placebo dose adjustments. To reduce the 197 
risk of serious adverse events, patients with abnormal thiopurine methyltransferase activity  198 
who are at increased risk of developing bone marrow suppression (low activity) or 199 
hepatotoxicity (high activity) with azathioprine were not enrolled.  200 
 201 
Follow-up and withdrawals 202 
Follow-up continued for a minimum of 48 weeks. Withdrawn subjects were returned to their 203 
referring ophthalmologist, however they were invited to attend assessment visits at the early 204 
(co-primary) and late (primary) outcome measure assessment times of 12 and 48 weeks to 205 
obtain data in accordance with the planned intention-to-treat analyses. Withdrawal criteria 206 
included worsening of disease (defined as a 2-point increase in clinical activity score or 207 
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development of optic neuropathy) and sustained blood test abnormalities (leucopenia, 208 
lymphopenia or abnormal liver function tests despite dose adjustment of azathioprine or 209 
placebo).  210 
 211 
Ethical approval and Trial Oversight 212 
The trial protocol was given a favourable opinion by the UK’s National Health Service South 213 
West Central Bristol Research Ethics Committee (REC reference: 05/Q2006/62). Clinical 214 
Trial Authorisation was given by the Medicines and Healthcare products Regulatory Agency 215 
(MHRA, reference: 03299/0003/001-0001; ISRCTN22471573) with the University of Bristol 216 
acting as the legal sponsor. Research governance and local Research and Development 217 
approvals were obtained across all sites prior to the start of recruitment. All participants gave 218 
written informed consent, and the conduct of the trial was subject to independent Data Safety 219 
Monitoring Committee and Trial Steering Committee review for the duration of the study.    220 
 221 
Outcomes 222 
As the principle objective of the trial was to evaluate treatment success and failure at the late 223 
time-point of 48 weeks, our primary outcome measures of disease severity binary clinical 224 
composite outcome measure (BOX 1) and Ophthalmopathy Index  (Supplementary Table 2) 225 
were selected to quantify the change in ocular deformity and visual dysfunction. An early, 226 
12-week, assessment of disease activity using the clinical activity score  was given lower 227 
priority and designated as a co-primary outcome (we expected that all participants would 228 
have a significant improvement in clinical activity score by 48 weeks in accordance with the 229 
natural history of the disease(28)). Secondary outcome measures included Total Eye Score  230 
Box 1 Calculation of the Binary Clinical Composite Outcome Measure   
Major Criteria  
 An improvement of ≥ 1 grade in diplopia score 
 An improvement of >8 degrees of eye movement in any direction  
 A reduction of ≥ 2 mm in proptosis  
 
Minor Criteria  
 A reduction of ≥ 2 mm in lid aperture  
 An improvement of ≥ 1 grade in soft tissue involvement 
 An improvement in best-corrected visual acuity of ≥ 1 line on the Snellen chart 
 Subjective improvement 
 
All items refer to the worst eye 
 
Response to treatment is calculated as follows  
Improved = improvement in ≥1 major criteria or ≥2 minor criteria  
No Change = improvement or deterioration in ≤1 minor criterion  
Worse = deterioration in ≥1 major or ≥2 minor criteria (even if other criteria improve) 
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(Supplementary Table 3) as an additional assessment of disease severity, patient-reported 231 
Graves’ Ophthalmopathy Quality of Life score and health economic indices.   232 
 233 
Statistical analyses 234 
Planned statistical analyses were pre-specified in our protocol paper, based on a sample size 235 
of 100 complete datasets at 48 weeks(26). These were undertaken according to CONSORT 236 
guidelines for RCTs. As required by the factorial design, the primary intention-to-treat 237 
analysis (ITT) combined the treatment groups to compare radiotherapy versus sham-238 
radiotherapy and azathioprine versus placebo for each of the two primary outcomes at 48 239 
weeks follow up. This analysis was made using multivariable regression models, adjusting 240 
for minimisation variables, the factorial design, and the value of the outcome variable at 241 
baseline. Statistical significance was defined in advance as a p-value of <0.05. Patients who 242 
had no outcome data for the primary analyses had data imputed using last observation carried 243 
forward if they had data available between 24-48 weeks. Analysis was performed for all 244 
primary outcomes (binary clinical composite outcome, ophthalmopathy index and clinical 245 
activity score).  Patients who withdrew from treatment due to side-effects, disease 246 
progression or personal preference, were encouraged to continue to attend for follow-up 247 
assessments and their data included in the intention-to-treat analyses. Since there were a large 248 
number of withdrawals from treatment (although most trial subjects still returned for 249 
assessment at the primary endpoint visit), a post-hoc as-per-protocol analysis was conducted 250 
including only patients who had not withdrawn and continued to receive their assigned 251 
treatment. Testing for interaction was performed using likelihood ratio tests. Additional 252 
sensitivity analyses were performed for the binary clinical composite outcome measure,  253 
including recoding those who withdrew due to deterioration, irrespective of their final status 254 
at 48 weeks (as they may have received alternative rescue therapy). The secondary outcome 255 
measures of Total Eye Score and Graves ophthalmopathy quality-of-life score were also 256 
compared across treatment groups, however patient-reported health economic analyses were 257 
not completed due to insufficient data.  All statistical analyses were undertaken using 258 
STATA version 12 (STATACORP, College Station, TX, USA).  259 
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Study Sponsor and role of the funding source 260 
The study sponsor was the University of Bristol. Funding was provided by the UK’s National 261 
Eye Research Centre, Above and Beyond and Moorfields Eye Charity supported by 262 
infrastructural investment from the National Institute for Health Research. The sponsor and 263 
funders had no role in the study design, in the collection, analysis, and interpretation of data, 264 
in the writing of the report or in the decision to submit the paper for publication. In addition, 265 
the corresponding author had full access to all of the data and the final responsibility to 266 
submit for publication (PNT RH CMD and RL had access to the raw data). 267 
 268 
Results 269 
Study Population 270 
126 people were recruited and randomised between February 2006 and October 2013 (71 271 
patients from Moorfields Eye Hospital, 34 from Bristol Eye Hospital, 7 from Manchester Eye 272 
Hospital, 5 from the Western Eye Hospital, 4 from University College London Hospital, 4 273 
from Gartnavel General Hospital and 1 from the University Hospital of Wales).  The flow of 274 
study participants is shown in Figure 1.  Data on both the primary outcomes at 48 weeks was 275 
provided by 103 participants, and these were analysed after data-lock (which included 276 
separate 3 year assessments on a minority of trial subjects) on 7
th
 October 2016. Baseline 277 
characteristics of the minimisation variables by group are shown in Table 1. Individuals 278 
allocated to azathioprine had a relatively lower proportion of non-Caucasian patients (not a 279 
criterion used for minimisation).  280 
 281 
Intention-to-treat  analysis 282 
Binary Clinical Composite Outcome Measure (primary outcome) 283 
The difference in the binary clinical composite outcome measure  between individuals 284 
randomised to azathioprine versus placebo tablets was on the threshold of our pre-specified 285 
significant p-value of <0.05, but did not meet this (the adjusted OR(adj) of the binary clinical 286 
composite outcome measure’s improvement on azathioprine was 2·56; 95%CI 0·98, 6·66; 287 
p=0·05, Table 2 Figure 2A). In contrast, there was no improvement with orbital radiotherapy 288 
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(OR(adj) =0·89, 95%CI 0·36, 2·23, p=0·80). Also, with regard to the factorial design, there 289 
was no evidence of interaction between azathioprine and radiotherapy (pint = 0·86) and the 290 
combination of azathioprine and orbital radiotherapy did not offer additional advantage over 291 
azathioprine alone. An overview of the impact on the binary clinical composite outcome 292 
measure of azathioprine and orbital radiotherapy is shown in Supplementary Figure 293 
2A+2B. Furthermore, additional sensitivity analyses in which withdrawn patients were coded 294 
to unfavourable outcomes regardless of their status at 48 weeks enhanced rather than lessened 295 
the improvement observed with azathioprine treatment (OR(adj) 3·65; 95%CI 1·34, 9·86; 296 
p=0·01) ( Supplementary Table 4). 297 
 298 
Ophthalmopathy Index (primary outcome) 299 
Analysis of all patients revealed that the ophthalmopathy index fell between week 12 (mean 300 
9.15, SD 0.39) and week 48 (mean 8.43, SD 0.38, p=0.04). No additional benefits were seen 301 
with either azathioprine or orbital radiotherapy. Individuals randomised to azathioprine had 302 
an adjusted Beta (B)(adj) of 0·46 (95%CI -1·04, 1·95; p=0·55) and in those randomised to 303 
orbital radiotherapy B(adj) was -0·89 (95%CI -2·34, 0·56; p=0·23) (Table 2). There was also 304 
no evidence of an interaction between azathioprine and radiotherapy in their effect on 305 
ophthalmopathy index (pint = 0·51). 306 
 307 
Clinical Activity Score  (co-primary outcome) 308 
Across all subjects, substantial improvement in median clinical activity score was seen over 309 
the study period from 5 (IQR 4 - 5) at baseline to 3 (IQR 2- 4; p<0·0001) at week 12, and 2 310 
(IQR 1-3; p<0·0001) at week 48 (Figure 2B, 2C). The majority of patients n=97 (70·0%) 311 
improved their clinical activity score by week 12 and 96 (98%) of the 98 patients with 312 
clinical activity score data at 48 weeks showed improvement in their clinical activity score 313 
versus baseline. No difference in the change in clinical activity score at 12 weeks was 314 
observed between individuals who received treatment with azathioprine versus not receiving 315 
azathioprine, or who received radiotherapy versus sham radiotherapy B(adj)= -0·01 (95%CI -316 
0·69, 0·68; p=0·99 – Table 2). There was no interaction between azathioprine and 317 
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radiotherapy in their effect on clinical activity score (pint= 0·48). There was also no evidence 318 
that azathioprine or orbital radiotherapy improved clinical activity score  at week 48 319 
(Supplementary Table 5).  320 
  321 
Total Eye Score (secondary outcome) 322 
Total Eye Score improved considerably over the study period with a mean at baseline of 15·1 323 
(95%CI 13·8, 16·3) falling to a mean of 9·36 (95%CI 8·12, 10·6; p <0·0001), but this was 324 
not affected by the addition of either azathioprine or orbital radiotherapy (Supplementary 325 
Table 6).  326 
 327 
Graves Ophthalmopathy Quality of Life (secondary outcome) 328 
Across all subjects, mean Graves ophthalmopathy quality of life visual function was higher 329 
(improved) at 12 weeks than at baseline (71·5 - 95%CI 66·1, 76·9 vs 64·1 - 95%CI 58·5, 330 
70·0; p=0·002), and at week 48 (75·5 - 95%CI 70·3, 80·7; p<0·001 versus baseline). Graves 331 
ophthalmopathy quality of life visual appearance was also higher at 12 weeks than at baseline 332 
(58·0 - 95%CI 52·5, 63·5 vs 53·2 - 95%CI 47·9, 58·6; p=0·007) and at week 48 (61·3 - 333 
95%CI 55·6, 67·1; p=0·001 versus baseline). Individuals who had an improvement in the 334 
binary clinical composite measure at week 48 had a higher Graves ophthalmopathy quality of 335 
life visual function (B=17·9 - 95%CI 7·07, 28·6; p<0·001) and a higher Graves 336 
ophthalmopathy quality of life visual appearance (B(adj)=11·5 - 95%CI 0·60, 23·6; p=0·06). 337 
There was no clear benefit from the addition of either azathioprine or orbital radiotherapy 338 
with regard to long-term Graves ophthalmopathy quality of life visual function or visual 339 
appearance (Supplementary Table 7, Supplementary Figure 3).   340 
 341 
As-per-protocol analysis 342 
Sixty individuals did not withdraw from study treatment before 48 weeks, completed their 343 
therapy period as allocated and were included in the as-per-protocol analysis. Ten of these 344 
patients were randomised to azathioprine and sham-radiotherapy, 17 were randomised to 345 
orbital radiotherapy and placebo alone, 12 were randomised to azathioprine and orbital 346 
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radiotherapy and 21 were randomised to sham-radiotherapy and placebo. Individuals in the 347 
as-per-protocol analysis appeared similar at baseline to those who were withdrawn from 348 
study treatment, although there was a higher percentage of non-Caucasians in those recruited 349 
from the larger study centres (Supplementary Table 8). 350 
 351 
In the as-per-protocol analysis, individuals randomised to receive azathioprine (n=22) had a 352 
higher odds ratio of improvement in their disease severity measured by the primary binary 353 
clinical composite outcome measure at 48 weeks (OR(adj)=6·83, 95%CI 1·66, 28·1; p=0·008). 354 
No benefit was seen in individuals randomised to receive orbital radiotherapy (OR(adj) 1·32, 355 
95%CI 0·36, 4·84; p=0·67, Table 3 Figure 2A).  To assess the effect of the duration of 356 
exposure to azathioprine we also conducted a comparative analysis of patients who continued 357 
to receive their allocated treatments at 12 weeks (n=84), 24 weeks (n= 79) and 36 weeks 358 
(n=68). This indicated that benefit was observed with ≥24 weeks of azathioprine exposure 359 
(Figure 2A, Supplementary Table 9 and Supplementary Figure 2A). Individuals 360 
receiving azathioprine also had a modest improvement in total eye score (B(adj)= -3·23, 361 
95%CI -6·42, 0·03; p=0·05, Supplementary Table 6). However, the as-per-protocol analysis 362 
did not reveal any benefit in ophthalmopathy index, clinical activity score or Graves 363 
ophthalmopathy quality of life of being randomised to receive either azathioprine or orbital 364 
radiotherapy (Table 3).  365 
 366 
Withdrawals from the study  367 
There was a high number of patients who withdrew from there allocated treatment (n=66, 368 
52·4%) (Figure 1), but the majority of these (n=45, 68.2%) returned for primary outcome 369 
evaluation. Twenty-five withdrawals were within the first 12 weeks (Figure 3). Withdrawals 370 
were less in non-Caucasians and in participants at two of the study centres (Moorfields and 371 
Bristol Eye Hospitals). Before 48 weeks there were 40 withdrawals in those randomised to 372 
receive azathioprine and 34 withdrawals in those randomised to receive orbital radiotherapy. 373 
Overall, 103 participants provided outcome data, of which 84 completed their allocated 374 
treatment of  radiotherapy or sham-radiotherapy, and 57 continued to take azathioprine or 375 
15 
 
 
 
 
 
placebo until 48 weeks.  Participants randomised to receive azathioprine had increased odds 376 
of withdrawal compared to those who did not OR(adj)=2·82 (95%CI 1·23, 6·45) p=0·01 377 
(Supplementary Table 10). The reasons for withdrawal are presented in Supplementary 378 
Figure 4. Patients receiving azathioprine had an increased odds of withdrawal due to 379 
precautionary blood test abnormalities or side effects OR=9·10 (95%CI 2·60, 31·9) p=0.001 380 
(Supplementary Table 11). However, unlike patients receiving placebo, patients taking 381 
azathioprine did not withdraw due to deterioration following cessation of steroid treatment at 382 
24 weeks (Figure 3C).  No baseline characteristics predicted withdrawal due to either 383 
azathioprine or orbital radiotherapy although the highest odds of withdrawal for disease 384 
deterioration was in the sham-radiotherapy and placebo group (Supplementary Table 12). 385 
There was no evidence of bias between treatment groups with regard to failure to provide 386 
data at 48 weeks (Supplementary Table 13 and Supplementary Table 14). 387 
 388 
Rescue therapy (including surgery) and adverse events 389 
Twenty-one (47%) of the trial subjects who withdrew from study treatment but provided 390 
outcome data were documented to have received additional therapy (Supplementary Table 391 
15). In most cases this was additional steroid therapy continuing until the endpoint of the 392 
study (week 48). Surgery was however required in 5 individuals, 3 of whom were in the 393 
azathioprine group (3 orbital decompressions, 1 lid surgery and 1 strabismus correction).  The 394 
number of individuals experiencing an adverse event did not differ across the treatment 395 
groups (azathioprine N=161, radiotherapy N=156). (Supplementary Table 16 and 396 
Supplementary Table 17).  397 
 398 
Masking 399 
Of the 69 patients and 71 doctors who recorded their perceived trial allocation for 400 
azathioprine or placebo on study completion or withdrawal, 30 patients (43%) and 29 doctors 401 
(41%) were incorrect. For radiotherapy and sham-radiotherapy, of the 70 patients and 67 402 
doctors, 23 patients (33%)  and 33 doctors (49%) were incorrect. 403 
 404 
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Discussion 405 
CIRTED fulfilled its target sample size, with more than 100 complete data sets at 48 weeks. 406 
Improvement in our primary, co-primary and secondary outcome measures (binary clinical 407 
composite outcome measure, clinical activity score and Graves ophthalmopathy quality-of- 408 
life score) across all groups confirmed the previously reported benefits of high dose systemic 409 
corticosteroid therapy in active moderate-to-severe thyroid eye disease (Figures 2B and 2C). 410 
In this context, orbital radiotherapy did not confer additional patient benefit in any pre-411 
specified outcome measure either in the short (12-week) or longer term (48-week). 412 
Radiotherapy was delivered early in the treatment (before 12 weeks); hence it is unlikely that 413 
this result is significantly confounded by the high withdrawal rate later in the treatment 414 
course.  415 
 416 
Less strong conclusions can be drawn with regard to azathioprine as comparatively few 417 
patients completed the full course of treatment. Nonetheless, the improvement in the binary 418 
clinical composite outcome measure observed in the azathioprine-treated group of subjects 419 
that was on the threshold of statistical significance in our intention-to-treat analysis (p=0.05) 420 
is likely to be real as the effect was sustained or enhanced in our sensitivity analyses 421 
(Supplementary Table 4, Supplementary Table 9). This is reinforced by the post-hoc as-422 
per-protocol analysis results which showed substantial benefit in favour of azathioprine 423 
(OR(adj)=6·83 p=0·008).  Of note, patient outcomes improved particularly in those receiving 424 
azathioprine for 24 weeks or more (figure 3A). Since steroid therapy was stopped at 24 425 
weeks (as is common practice in thyroid eye disease), this suggests that the key benefit of 426 
azathioprine is to prevent relapse after withdrawal of steroids. This observation is consistent 427 
with the generally recognised role of azathioprine as a steroid-sparing agent, used to prevent 428 
relapse in other autoimmune conditions, and this is further reinforced by the findings of the 429 
MINGO study using an alternative antiproliferative agent (mycophenolate sodium) in thyroid 430 
eye disease. Furthermore, this view is supported by analysis of the binary clinical composite 431 
outcome measure components indicating that azathioprine did not increase major 432 
improvement rates overall but did reduce major deterioration in the binary clinical composite 433 
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outcome measure (p=0.004, Supplementary Figure 2A), plus the observation that late 434 
withdrawal (after 24 weeks) due to deterioration was not seen in patients treated with 435 
azathioprine (Figure 3C).  436 
 437 
A major feature of this study was the high rate of withdrawal from patients’ allocated 438 
treatment. In all study groups, early withdrawals (before 24 weeks) due to disease 439 
deterioration were seen as the steroid dose was reduced and this was not mitigated by orbital 440 
radiotherapy (Figure 3C). Our masked protocol necessarily set strict thresholds for 441 
withdrawal due to abnormal monitoring blood tests (white cell counts and liver function), 442 
which together with treatment side-effects led to more common withdrawals in those 443 
allocated to azathioprine (Figure 3B). Hence, it is likely that in usual clinical practice 444 
azathioprine treatment would be continued in a higher percentage of patients.  Importantly, 445 
many of those withdrawing from treatment still completed their study follow-up visits until 446 
the primary endpoint (48 weeks), resulting in the outcomes for over 80% of randomised 447 
subjects being available for our intention-to-treat analysis. 448 
 449 
The other key methodological point to consider is our use of two primary outcome measures 450 
at 48 weeks. As we have previously published (26), this was because of the lack of fully 451 
validated long-term disease severity measures in thyroid eye disease. We also wished to 452 
mitigate the theoretical limitations of composite binary scoring systems, in particular with 453 
regard to baseline variability between treatment groups, by using a continuous variable with 454 
regression analyses in mind. However, our minimisation strategy was successful in balancing 455 
baseline features across trial arms and the binary clinical composite outcome measure has 456 
since become the preferred end-point for thyroid eye disease studies as it is more sensitive to 457 
change(21, 23). We have therefore focused on this rather than the ophthalmopathy index 458 
which has not been a primary endpoint in other recent trials.  459 
 460 
The key strengths of this RCT include the use of minimisation, low rates of loss-to-follow-up 461 
(including of withdrawn patients) and the success of our extensive efforts to mask both 462 
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azathioprine and radiotherapy treatment allocation to both the patients and clinicians 463 
(including the use of sham radiotherapy). In addition, we observed no evidence of interaction 464 
between the two interventions (radiotherapy and azathioprine), which is supportive of our 465 
choice of a factorial design. Conversely, a major limitation of our study was the high 466 
withdrawal rate, particularly for those randomised to receive azathioprine. Therefore, our 467 
conclusions with regard to the efficacy of this treatment need to be interpreted with caution. 468 
We also permitted patients to enrol in the trial and start systemic corticosteroid therapy 469 
before their thyroid function tests were normalised. This potentially confounds the 470 
interpretation of our data with the benefit of returning to euthyroidism, but we judged 471 
intervening with immunosuppression in the early active phase of disease to outweigh this 472 
risk. Furthermore, given that demonstration of clinical improvement following a 2-week 473 
course of high-dose oral steroids was a key entry criterion, our results cannot be extrapolated 474 
to infer the value of radiotherapy or azathioprine in patients with steroid refractory disease. 475 
Oral corticosteroid therapy was used in this study and given to all study participants as this 476 
was the standard of care in the study centres at the time of trial initiation and remains 477 
commonly prescribed in many regions of the world including North America (29).  478 
 479 
In summary, our results suggest that low-dose orbital radiotherapy confers no additional short 480 
or long-term treatment benefit when combined with a six-month reducing course of oral 481 
corticosteroids. Our findings with regard to azathioprine are less definitive, but taken together 482 
indicate that, if tolerated, azathioprine improves 48-week clinical outcomes in patients with 483 
active moderate-to-severe thyroid eye disease. This supports the use of long-term 484 
antiproliferative treatments in combination with systemic corticosteroids for the treatment of 485 
active moderate-to-severe thyroid eye disease, consistent with established practice in other 486 
autoimmune conditions.   487 
 488 
  489 
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Table 1 Characteristics of the Four Trial Groups 
Variable RT + Aza   Sham + Aza RT + Placebo Sham + Placebo 
Number of patients 31 31 32 32 
Age at enrollment 50.4 (10.4) 51.4 (9.53) 46.1 (11.5) 49.2 (11.7) 
Age ≥ 60 years (%) 16.1 12.9 18.8 15.6 
Disease Duration 
(months) 
6.01 (11.4) 5.01 (4.39) 5.50 (9.41) 7.29 (12.6) 
Duration > 6 months 35.5 22.6 34.4 28.1 
Ethnicity 
(% Non Caucasian) 
12.9 22.6 40.6 34.4 
% Male 29.0 22.5 28.1 25 
% Smoker 54.8 48.4 34.4 46.9 
Thyroid State (%) 
Euthyroid 
Hyperthyroid 
Hypothyroid 
 
9.7 
83.9 
6.5 
 
12.9 
74.2 
12.9 
 
9.7 
80.7 
9.7 
 
6.3 
81.3 
12.5 
Previous steroid use 
(%) 
16.1 6.5 12.5 15.6 
Study Centre (%) 
Moorfields or Bristol 
vs the other centres) 
83.9 83.9 81.3 84.4 
CAS Score 
2-3 
4-5 
6-7 
 
17.9 
53.6 
28.6 
 
16.7 
70.0 
13.3 
 
24.1 
55.2 
20.7 
 
9.4 
68.9 
21.9 
TES Score 
<22 
>22 
 
77.4 
22.5 
 
83.3 
16.7 
 
81.3 
18.8 
 
90.6 
9.4 
 
Aza = Azathioprine, RT = Radiotherapy 
CAS = Clinical Activity Score TES = Thyroid Eye Score 
 
Table 1
Table 2 Intention to treat analysis Binary Composite Clinical Outcome, Ophthalmopathy Index and Change in  
Clinical Activity Score 
 Outcome OR B 95%CI P OR* B* 95%CI* P* 
Aza Binary Clinical 
Composite 
Outcome1 
(N=103)† 
1.99 - (0.88, 4.51) 0.10 2.56  0.98, 6.66 0.05 
  RT 1.07 - (0.47, 2.39) 0.87 0.89  0.36, 2.23 0.80 
  AzaRT 2.16 - (0.85, 5.47) 0.11 2.52  0.87, 7.29 0.09 
Aza Ophthalmopathy 
Index 
Week 482 
N=109 
- 0.50 (-1.00, 2.00) 0.51 - 0.46 -1.04, 1.95 0.55 
  RT - -0.41 (-1.91, 1.09) 0.59 - -0.89 -2.34, 0.56 0.23 
  AzaRT - -0.43 (-2.21, 1.35) 0.63 - -0.78 -2.52, 0.96 0.37 
Aza 
Change in Clinical 
Activity Score3 
 
- -0.48 (-1.17, 0.21) 0.17 - -0.54 -1.25, 0.16 0.13 
RT Week 12 - -0.08 (-0.78, 0.62) 0.82 - -0.01 -0.69, 0.68 0.99 
AzaRT (N=107) - -0.71 (-1.52, 0.10) 0.09 - -0.64 -1.46, 0.18 0.13 
 
* Adjusted for age group, ethnicity, smoking status, gender, thyroid state, disease duration, study centre, recent steroid use, 
baseline CAS score, baseline TES score. For Azathioprine and Radiotherapy, this analysis is also adjusted for the other treatment 
option (but not the combined Azathioprine-Radiotherapy group) 
OR= Odds ratio, B = Beta Coefficient 
95% CI = 95% confidence interval 
p = p value against the null hypothesis of no association 
Aza = Randomised to Azathioprine, RT = Randomised to Radiotherapy,  
AZART = Randomised to Azathioprine and Radiotherapy    
 
1 6 individuals with last data carried forward 
2 8 individuals with last data carried forward 
3 10 individuals with last data carried forward 
 
†Absolute values 22/50 patients who received azathioprine improved versus 16/54 who did not receive azathioprine.  
19/50 patients who received orbital radiotherapy improved vs 19/54 who did not receive orbital radiotherapy. 
 
Table 2
Table 3 As per protocol analysis Binary Composite Clinical Outcome, Ophthalmopathy Index and Change in Clinical 
Activity Score 
 Outcome OR/B 95%CI P OR/B*# 95%CI* P* 
Aza Binary Clinical 
Composite 
Outcome† 
Week 48 
(N=58)† 
5.21 (1.62, 16.8) 0.006 6.83 (1.66, 28.1) 0.008 
  RT 1.49 (0.53, 4.21) 0.45 1.32 (0.36, 4.84) 0.67 
  AzaRT 7.24 (1.40, 37.4) 0.02 16.1 (2.03, 127.6) 0.009 
Aza 
Opthalmopathy 
Index Week 48 
(N=59) 
-0.16 (-2.12, 1.80) 0.87 -0.85 (-2.65, 0.95) 0.35 
  RT -0.20 (-2.10, 1.69) 0.83 -0.79 (-2.52, 0.94) 0.36 
  AzaRT -1.34 (-3.66, 0.99) 0.26 -2.02 (-4.13, 0.09) 0.06 
Aza 
Change in 
Clinical Activity 
Score 
-0.63 (-1.37,  0.12) 0.10 -0.54 (-1.29, 0.20) 0.15 
RT Week 12 -0.03 (-0.79, 0.73) 0.94 0.10 (-0.66, 0.85) 0.80 
AzaRT (N=88) -0.86 (-1.73, 0.002) 0.05 -0.66 (-1.55, 0.22) 0.14 
 
** Adjusted for age group, ethnicity, smoking status, gender, thyroid state, disease duration, study centre, recent steroid use, 
baseline CAS score, baseline TES score. For Azathioprine and Radiotherapy, this analysis is also adjusted for the other treatment 
option (but not the combined Azathioprine-Radiotherapy group)  
OR= Odds ratio, B = Beta Coefficient 
95% CI = 95% confidence interval 
p = p value against the null hypothesis of no association 
Aza = Randomized to Azathioprine, RT = Randomized to Radiotherapy,  
AZART = Randomized to  Azathioprine and Radiotherapy 
 
†Absolute Values 15/21 patients who completed protocol on azathioprine improved vs 12/37 who did not receive azathioprine 
14/27 patients who completed protocol on orbital radiotherapy improved vs 13/31 who did not receive orbital radiotherapy 
Table 3
Figure 1 Consort Diagram
Potential Recruits 298
Patients fully screened in Unit/had 
patient info sent
131  patients ineligible 
69  -  Patient is not interested in participating in research
20 -  Not active enough
15 - Miscellaneous 
6   -  Abnormal TPMT
6 -  Optic neuropathy
3  -  Pregnant, or planning pregnancy
2 -  Abnormal liver function tests
2 -  Recent steroid use
1 -  Awaiting corneal graft
1 -  Not GO
1 -  HIV+
1 -  TB
1 -  Patient does not want to take steroids
1 -  Endocrinologist wants to start radioiodine
1 -  History of carcinoma
1 -  Has had radio iodine within last 3 months
41 patients consented but ineligible to proceed with randomisation 
19 -  Abnormal blood test results
10 -  Lack of effi cacy of treatment
5 -  Patient is not interested in participating in research
3 -  Not active enough clinically 
2 -  Contraindication to prednisolone 
1 -  Excluded due to Amblyopia
1 -  GP recommended patient should not be in the study
126 patients randomized
103 patients provided data on both 
primary endpoints at week 48
Sham Radiotherapy 
and Azathioprine 
(N=31) 
Sham Radiotherapy 
and Placebo
(N=32)
Radiotherapy and 
Azathioprine 
(N=31)
20† 
withdrew
21††
withdrew
10 
remained
16 provided 
FU data
13 provided 
FU data
16†
withdrew
Radiotherapy 
and Placebo
(N=32)
167 
enrolled
11 
remained
10 provided
FU data
16 
remained
12†† 
withdrew
7 provided 
FU data
20
remained
† 1 patient provided data for OI but not BCCOM
†† 2 patients provided data for OI but not BCCOM
Figure 1
Figure 2A Odds ratio of having an improved BCCOM score by treatment and duration in study
Aza ITT (N=103)
RT ITT (N=103)
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Figure 2A
Figure 2B Boxplot of CAS at baseline, week 12 and week 48 by whether a participant was randomised 
to azathioprine
(p<0.0001)
(p=0.002)
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Figure 2B
Figure 2C Boxplot of CAS at baseline, week 12 and week 48 by whether a participant was randomised 
to radiotherapy
(p<0.0001)
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Figure 2C
Figure 3A Kaplan Meier showing withdrawals from treatment (all reasons)
Number at risk
RT and AZA
RT and Placebo
Sham and AZA
Sham and Placebo
31
32
31
32
23 
23 
22 
29
20 
23 
15 
26
15
20
12
23
13
16
10
21
RT and AZA RT and Placebo
Sham and AZA Sham and Placebo
P
ro
p
o
rt
io
n
 c
o
m
p
le
te
d
Withdrawal Overall
Time following randomisation (weeks)
0
0
. 2
5
0
. 0
0
0
. 5
0
0
. 7
5
1
. 0
0
12 24 36 48
Figure 3A
Figure 3B Kaplan Meier showing withdrawals from treatment (side effects and abnormal blood test results)
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Figure 3B
Figure 3C Kaplan Meier showing withdrawals from treatment (deterioration)
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Abstract 56 
Background 57 
Thyroid eye disease (TED) is ana disabling inflammatory orbital condition which causes 58 
visual dysfunction and psychological morbidity. Current evidenceStandard treatment is 59 
conflicting about thewith systemic corticosteroids, but the additional benefit of orbital 60 
radiotherapy and antiproliferative immunosuppression in addition to systemic corticosteroid 61 
treatment. The aim of this study was to evaluate the efficacy of orbital radiotherapy (RT) and 62 
the antiproliferative drug azathioprine (AZA) in combination with oral corticosteroids for 63 
patients with active moderate-to-severe TED.is unclear.  64 
 65 
Methods  66 
Participants all received a standardised tapering 6-month 24 week course of oral prednisolone 67 
and were also randomly allocatedrandomised to receive RTradiotherapy or sham-68 
RTradiotherapy, and AZAazathioprine or placebo, in a 2x2 factorial design using 69 
minimisation to reduce baseline discrepancies between treatment groups.. The primary 70 
outcome measure was improvement in disease severity assessed withoutcomes were a binary 71 
composite clinical outcome score and ophthalmopathy index at 48 weeks. This study reports 72 
the main trial analysis using both intention-to-treat and as-per-protocol analyses and clinical 73 
activity score at 12 weeks. (ISRCTN 22471573).   74 
 75 
Findings 76 
126 subjectsadults with active moderate-to-severe thyroid eye disease were randomised and 77 
complete primary. 103 provided outcome data were available in 101 (80%). Sixty-six (52%) 78 
withdrew from their , of which 84 completed their allocated treatment allocation beyond the 79 
period of of  radiotherapy/ or sham-radiotherapy but before the primary end point (61% in 80 
AZA, 40% in RT). Withdrawal due to abnormal blood tests or side-effects was more frequent 81 
with AZA (adjusted odds ratio [OR(adj)]=9·10; 95%CI 2·60, 31·9; p=0.001). In an , and 57 82 
continued to take azathioprine or placebo until 48 weeks. Pre-specified intention-to-treat 83 
analysis, of the binary clinical composite outcome measure revealed an odds of improvement 84 
for azathioprine of OR(adj)=2·56 (95%CI 0·98, 6·66; p=0·05) for AZA and for radiotherapy of 85 
OR(adj)=0·89 (95%CI 0·36, 2·23; p=0·80 for RT). For). In a post-hoc analysis of patients 86 
completing their allocated therapy, improvement was more frequent on AZAazathioprine 87 
(OR(adj)=6·83; 95%CI 1·66, 28.1; p=0·008 than RTradiotherapy (OR(adj)=1·320·71; 95%CI 88 
0·36, 4·8426, 1·95; p=0·67).  50).  The ophthalmopathy index, clinical activity score and 89 
number of adverse events (azathioprine N=161, radiotherapy N=156) did not differ between 90 
treatment groups. 91 
 92 
Interpretation  93 
In patients receiving a 24-week course of oral prednisolone, no additional treatment benefit 94 
for 24 weeks, the addition of radiotherapy was seen with RT.not beneficial. With regard to 95 
AZAazathioprine, our conclusions are limited by a high number of withdrawals from 96 
treatment. However, ourthese results suggest that patients who completed AZA therapy had a 97 
 4 
 
 
 
 
 
significant reduction in their disease severity at 48 weeks was reduced in participants who 98 
completed azathioprine treatment. 99 
  100 
Funding 101 
The National Eye Research Centre, Above and Beyond and Moorfields Eye Charity, 102 
supported by infrastructural investment to the host institutions from the National Institute for 103 
Health Research.  104 
 105 
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  107 Research in Context 
 Active moderate-to-severe thyroid eye disease is currently treated with systemic corticosteroids, but 
outcomes are often sub-optimal. Corticosteroids are most effective when administered intravenously, 
but this is inconvenient, and oral administration remains common in global clinical practice. 
However, uncertainty remains about the additional benefit of orbital radiotherapy and antiproliferative 
immunosuppressive drugs.  
 
Evidence before this study 
Previous retrospective case series have reported that the antiproliferative immunosuppressive drug 
azathioprine reduces disease severity and the need for rehabilitative surgery, but no prior RCTs have 
been completed. The evidence base for orbital radiotherapy is stronger, but conflicting, especially in 
the context of systemic corticosteroid treatment.  
 
Added value of this study 
Eighty per cent of subjects completed radiotherapy, but no significant short (12 week) or long-term 
(48 week) benefit resulted over and above the improvement seen with a 24-week tapering course of 
oral corticosteroids.  Less strong conclusions can be drawn with regard to azathioprine, as many 
patients did not complete treatment due to abnormalities in monitoring blood tests or side-effects, but 
those that continued azathioprine for more than 24 weeks benefitted, predominantly due to a 
prevention of deterioration after the end of corticosteroid treatment.  
 
Implications of all the available evidence 
These results do not support the use of radiotherapy in thyroid eye disease in patients also treated with 
systemic corticosteroids. They also provide evidence in favour of the use of anti-proliferative 
immunosuppressive agents such as azathioprine beyond the period of corticosteroid therapy to 
improve long-term clinical outcomes. 
 
Research in Context 
 Active moderate-to-sever  thyroid ey  disease (TED) is curr ntly treated with sy t mic 
cortic ster ids, but outcomes are often sub-optimal. Despit  the futur  pro ise of high-cost 
monoclonal antibody therapies, major uncertainty in real-world healthcare provision remai s about 
whether antiproliferative im unosuppressive rugs and orbital radiotherapy provide dditi nal 
benefit over systemic corticosteroid treatment. Current global clinical practice is consequently highly 
variable. 
 
Evidence before this study 
Scarcity of patients and funding ha  limited high-quality research in this field. Previous retrospective 
case series have r ported that the antipr liferative immunosuppre sive drug azathiopri e (AZA) 
reduces disease severity and the ne d for rehabilitative surgery, but no prior RCTs have been 
completed. The evidence base for orbital radiotherapy (RT) is stronger, but conflicting, especially in 
the context of  systemic corticosteroid treatment. 
 
Added value of this study 
No significant short (12 week) or longterm (48 week) benefit was seen from the addition f RT over 
and above the impr vement seen with the 24 week high dos  tapering oral steroid cour e. Less strong 
conclusions can be drawn with regard to AZA as many patients did not compl te the treatme t due to 
abnormalities i  monito ing bl od tests or si e-effects, but those that continued AZA for more than 24 
weeks benefitted from treatment, predominantly due to a prevention of deterioration after the end of 
the steroid course.  
 
Implications of all the available evidence 
These res lts question the role of RT in TED atients when added t  treatment with systemic 
corticoster ids. Th y also pr vide evidence in favour of the use of anti-proliferative 
immunosuppressive agents such as AZA beyond the period of steroid therapy to improve long-term 
outcomes. 
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Introduction 108 
Active moderate-to-severe thyroid eye disease (TED, also known as Graves’ orbitopathy or 109 
thyroid associated orbitopathy) occurs in 5-10% of cases of Graves’ disease1.(1). It can be 110 
both visually disabling and cosmetically disfiguring and substantially impairs quality of 111 
life(1-3). The aim of treatment is to suppress orbital inflammation and reduce consequent 112 
tissue re-modelling in extraocular muscles, orbital fat and other periocular soft tissues(4, 5). 113 
Immunosuppressive therapies, in particular corticosteroids(1, 4, 6), are the mainstay of 114 
treatment for active moderate-to-severe TED
1
., are the mainstay of treatment for active 115 
moderate-to-severe thyroid eye disease (1). However, they are typically withdrawn after 24 116 
weeks of treatment to limit cumulative toxicity regardless of whether they are administered 117 
via the oral or intravenous route(7), and given that active disease lasts 1–2 years, recurrence 118 
at the time of withdrawal often occurs(1, 7-9).   119 
 120 
Consequently, the avoidance of corticosteroid side-effects, improvement in treatment efficacy 121 
and maintenance of long-term disease control are major goals for the field of TEDthyroid eye 122 
disease as a whole. However, efforts to use monoclonal antibody therapies to more 123 
selectively suppress disease are still either early in their route to market(10), or have failed to 124 
demonstrate definitive treatment benefit(11, 12). Hence, given the proven short-term efficacy 125 
of corticosteroids in the treatment of active moderate-to-severe TEDthyroid eye disease, it is 126 
likely that they will remain the gold-standard first-line treatment for several years to come, 127 
and the need to find adjunctive therapies to augment and sustain their benefit remains very 128 
real. 129 
 130 
To date, the only non-corticosteroid conventional immunosuppressant drug to have been 131 
evaluated in RCTs is cyclosporine A(13, 14), which was found to be beneficial, but its use 132 
has not been widely adopted because of concerns about side-effects(6). An alternative 133 
strategy is to use an antiproliferative agent such as azathioprine as it is better tolerated than 134 
cyclosporine A(15, 16) and although ineffective as monotherapy
17
,(17), retrospective data 135 
indicates that in combination with corticosteroids it reduces disease severity and the need for 136 
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rehabilitative surgery
18
.  In addition to immunosuppression, non-pharmaceutical treatment of 137 
active TED(18).  In addition to immunosuppression, non-pharmaceutical treatment of active 138 
thyroid eye disease  with orbital radiotherapy has been advocated for decades, and older 139 
RCTs demonstrated that this was more effective when used in combination with 140 
corticosteroids(19, 20). . However, subsequent studies either questioned the role of orbital 141 
radiotherapy or concluded that its benefit was limited to improvement in oculomotility(21-142 
23). This has generated significant controversy, in particular due to concerns about the entry 143 
criteria, trial design and radiotherapy administration in Gorman et al’s paper(22), which has 144 
led to disparity in practice. Orbital radiotherapy has now been largely abandoned in North 145 
America, whereas in European centres, including the UK, it is still routinely used(6, 23-25).  146 
As it is administered daily over 2-3 weeks and patients are typically of working age, this also 147 
has significant implications for the use of healthcare resources and patients’ time. 148 
Furthermore, only two relatively small studies have evaluated the additional effect of 149 
radiotherapy when combined with a high -dose course of systemic corticosteroids(19, 20), 150 
and clinical outcomes beyond 24 weeks have rarely been reported for any intervention in 151 
TED.thyroid eye disease. We therefore sought to evaluate the long-term benefit of low-cost 152 
orbital radiotherapy and antiproliferative immunosuppression and orbital radiotherapy with 153 
azathioprine in the context of sustained systemic corticosteroid treatment for active moderate-154 
to-severe TEDthyroid eye disease . 155 
 156 
Methods 157 
Study design and participants 158 
We undertook this factorial design multicentre, double masked RCT in 6 centres in the UK. 159 
Patients  aged 20-75 years were recruited to receive either azathioprine or placebo, plus either 160 
orbital radiotherapy or sham-radiotherapy, in combination with a standardised 24-week 161 
tapering oral prednisolone regime (Supplementary Table 1 and Supplementary Figure 1). 162 
In brief, all patients received an initial oral prednisolone dose of 80mg / day, which reduced 163 
to 20mg / day by 6 weeks, 10mg / day by 15 weeks and 5mg / day by 21 weeks. In 164 
accordance with the factorial design, study recruits were then randomly allocated into 4 165 
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groups 2 weeks after starting corticosteroids: azathioprine plus orbital radiotherapy, 166 
azathioprine plus sham-radiotherapy, placebo plus orbital radiotherapy, or placebo plus 167 
sham-radiotherapy.  Full protocol details, including pre-specified primary and secondary 168 
outcome measures and statistical analyses, have been previously peer-reviewed, published 169 
and are openly available
26
.(26). Trial registration was assigned retrospectively on 1 February 170 
2006 (ISRCTN22471573) following regulatory permissions, but prior to starting recruitment. 171 
 172 
Eligible patients had  a clinical activity score
27
 (CAS)Eligible patients had  a clinical activity 173 
score(27) ≥ 4 (worst eye) OR ≥ 2 (worst eye) with a history of proptosis or motility 174 
restriction of less than 6 months duration. They were also were required to have a past or 175 
present history of abnormal thyroid function or a clinical diagnosis of TEDthyroid eye 176 
disease made and confirmed by ≥2 muscle involvement on computed tomography or 177 
magnetic resonance imaging scan. CASThe clinical activity score was scored out of 7 at the 178 
enrolment visit as its last 3 items (decreasing proptosis, decreasing visual acuity and 179 
decreasing eye movement) require a change in consecutive measurements to be calculated. 180 
This therefore cannot be done at the first assessment, but at all subsequent visits CASclinical 181 
activity score was scored out of 10.  If study recruits either had a < 6 month history of 182 
TEDthyroid eye disease (defined as time since first symptom) or an improvement in any item 183 
of CASclinical activity score 2 weeks after starting the trial prednisolone regime, they were 184 
considered to have active disease and were randomised at the second trial visit. Key 185 
exclusion criteria included age <20 or >75 years, dysthyroid optic neuropathy, abnormal 186 
thiopurine methyltransferase (TPMT) activity and use of radioiodine or any 187 
immunomodulatory or cytotoxic drugs within the last 3 months (thyroidectomy was 188 
permitted).  189 
 190 
Randomisation and masking 191 
Patients’ eligibility for the study was assessed by the ophthalmic investigators at each trial 192 
centre. Allocation of trial participants 193 Formatted: Font: Not Italic, English
(United States)
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Patients were allocated to treatment groups was by remote computerised randomization. 194 
Minimisationrandomisation and minimisation was used to reduce baseline disparities in 195 
potential confounding variables between trial interventions. These included smoking status at 196 
the time of TEDthyroid eye disease diagnosis, thyroid status on enrolment, previous 197 
corticosteroid use, gender, disease severity, study centre, disease duration, age greater than 60 198 
years and disease activity.  Patients, clinicians (both ophthalmic and endocrine) and data 199 
analysts were all masked. Only the trial co-ordinators (who monitored trial subjects blood 200 
results), pharmacists and radiographers were unmasked. The success of masking for 201 
ophthalmic investigators and patients was assessed at study completion or withdrawal by 202 
asking them to declare which treatments they thought had been administered.  203 
 204 
Interventions 205 
Procedures 206 
Orbital radiotherapy 207 
Twenty gray (Gy) of radiation was administered to the retrobulbar orbit in 10-12 fractions 208 
over 2 to 3 weeks. Subjects receiving sham-radiotherapy also attended and underwent all the 209 
same procedures other than no radiation being delivered. Extensive effort was used across 210 
trial centres to ensure participants were unable to identify if they were receiving a sham 211 
therapy, including use of a noise emitting device to simulate treatment administration
26
(26) 212 
(for details of the radiotherapy procedures at each trial centre see Supplementary Text 2) 213 
 214 
Azathioprine 215 
Treatment dose varied between 100mg and 200mg daily (dispensed as 50 mg tablets), 216 
depending on body weight. Matched placebo tablets and packaging were used and the dose 217 
was adjusted according to a standard algorithm dependent on patients’ blood test results. 218 
Again, extensive effort was taken to ensure participants were unaware if they were receiving 219 
placebo, including identical blood tests and random placebo dose adjustments. To reduce the 220 
risk of serious adverse events, patients with abnormal TPMTthiopurine methyltransferase 221 Formatted: English (United States)
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activity  who are at increased risk of developing bone marrow suppression (low activity) or 222 
hepatotoxicity (high activity) with azathioprine were not enrolled.  223 
 224 
Follow-up and withdrawals 225 
Follow-up continued for a minimum of 48 weeks. Withdrawn subjects were returned to their 226 
referring ophthalmologist, however they were invited to attend assessment visits at the early 227 
(co-primary) and late (primary) outcome measure assessment times of 12 and 48 weeks to 228 
obtain data in accordance with the planned intention-to-treat analyses. Withdrawal criteria 229 
included worsening of disease (defined as a 2 -point increase in CASclinical activity score or 230 
development of optic neuropathy) and sustained blood test abnormalities (leucopenia, 231 
lymphopenia or abnormal liver function tests despite dose adjustment of AZAazathioprine or 232 
placebo).  233 
 234 
Ethical approval and Trial Oversight 235 
The trial protocol was given a favourable opinion by the UK’s  National Health Service 236 
South West Central Bristol Research Ethics Committee (REC reference: 05/Q2006/62). 237 
Clinical Trial Authorisation was given by the Medicines and Healthcare products Regulatory 238 
Agency (MHRA, reference: 03299/0003/001-0001; ISRCTN22471573) with the University 239 
of Bristol acting as the legal sponsor. Research governance and local Research and 240 
Development approvals were obtained across all sites prior to the start of recruitment. All 241 
participants gave written informed consent, and the conduct of the trial was subject to 242 
independent Data Safety Monitoring Committee and Trial Steering Committee review for the 243 
duration of the study.    244 
 245 
OutcomesOutcome measures 246 Formatted: Font: Italic
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 247 
As the principle objective of the trial was to evaluate treatment success and failure at the late 248 
time-point of 48 weeks, our primary outcome measures of disease severity (Binary 249 
Composite Outcome Measure [BCCOM] binary clinical composite outcome measure (BOX 250 
1;) and Ophthalmopathy Index [OI]  (Supplementary Table 2) were selected to quantify the 251 
change in ocular deformity and visual dysfunction. An early, 12-week, assessment of disease 252 
activity using the CASclinical activity score  was given lower priority and designated as a co-253 
primary outcome (we expected that all participants would have a significant improvement in 254 
CASclinical activity score by 48 weeks in accordance with the natural history of the 255 
disease
28
). Secondary outcome measures included Total Eye Score (TES) (Supplementary 256 
Table 3) as an additional assessment of disease severity, and the patient-reported Graves’ 257 
Ophthalmopathy Quality of Life (GO-QoL) score.(28)). Secondary outcome measures 258 
included Total Eye Score  (Supplementary Table 3) as an additional assessment of disease 259 
Box 1 Calculation of the Binary Clinical Composite Outcome Measure   
Major Criteria  
 An improvement of ≥ 1 grade in diplopia score 
 An improvement of >8 degrees of eye movement in any direction  
 A reduction of ≥ 2 mm in proptosis  
 
Minor Criteria  
 A reduction of ≥ 2 mm in lid aperture  
 An improvement of ≥ 1 grade in soft tissue involvement 
 An improvement in best-corrected visual acuity of ≥ 1 line on the Snellen chart 
 Subjective improvement 
 
All items refer to the worst eye 
 
Response to treatment is calculated as follows  
Improved = improvement in ≥1 major criteria or ≥2 minor criteria  
No Change = improvement or deterioration in ≤1 minor criterion  
Worse = deterioration in ≥1 major or ≥2 minor criteria (even if other criteria improve) 
 
 
 
 
Box 1 Calculation of the Binary Clinical Composite Outcome Measure (BCCOM)  
BCCOM Major Criteria  
 An improvement of ≥ 1 grade in diplopia score 
 An improvement of >8 degrees of eye movement in any direction  
 A reduction of ≥ 2 mm in proptosis  
 
BCCOM Mi r Criteria  
 A reduction of ≥ 2 mm in lid aperture  
 An improvement of ≥ 1 grade in soft tissue involvement 
 An improvement in best-corrected visual acuity of ≥ 1 line on the Snellen chart 
 Subjective improvement 
 
All items refer to th  worst eye 
 
Response to t eatment is calculated as follows  
Improved = improvement in ≥1 major criteria or ≥2 minor criteria  
No Change = improvement or deterioration in ≤1 minor criterion  
Worse = deterioration in ≥1 major or ≥2 minor criteria (even if other criteria improve) 
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severity, patient-reported Graves’ Ophthalmopathy Quality of Life score and health economic 260 
indices.   261 
 262 
Statistical analyses 263 
Planned statistical analyses were pre-specified in our protocol paper, based on a sample size 264 
of 100 complete datasets at 48 weeks
26
.(26). These were undertaken according to CONSORT 265 
guidelines for RCTs. As required by the factorial design, the primary intention -to -treat 266 
analysis (ITT) combined the treatment groups to compare radiotherapy versus sham-267 
radiotherapy and azathioprine versus placebo for each of the two primary outcomes at 48 268 
weeks follow up. This analysis was made using multivariable regression models, adjusting 269 
for minimisation variables, the factorial design, and the value of the outcome variable at 270 
baseline. Statistical significance was defined in advance as a p-value of <0.05. Patients who 271 
had no outcome data for the primary analyses had data imputed using last observation carried 272 
forward if they had data available between 24-48 weeks. Analysis was performed for all 273 
primary outcomes (binary clinical composite outcome, ophthalmopathy index and clinical 274 
activity score).  Patients who withdrew from treatment due to side-effects, disease 275 
progression or personal preference, were encouraged to continue to attend for follow-up 276 
assessments and their data included in the ITTintention-to-treat analyses. Since there were a 277 
large number of withdrawals from treatment (although most trial subjects still returned for 278 
assessment at the primary endpoint visit), a secondarypost-hoc as-per-protocol (APP) 279 
analysis was conducted including only patients who had not withdrawn and continued to 280 
receive their assigned treatment. Testing for interaction was performed using likelihood ratio 281 
tests. Additional sensitivity analyses were performed for the BCCOM primarybinary clinical 282 
composite outcome measure,  including recoding those who withdrew due to deterioration, 283 
irrespective of their final status at 48 weeks (as they may have received alternative rescue 284 
therapy). The secondary outcome measures of Total Eye Score and Graves ophthalmopathy 285 
quality-of-life score were also compared across treatment groups, however patient-reported 286 
health economic analyses were not completed due to insufficient data.  All statistical analyses 287 
were undertaken using STATA version 12 (STATACORP, College Station, TX, USA).  288 
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 289 
Study Sponsor and role of the funding source 290 
The study sponsor was the University of Bristol. Funding was provided by  the UK’s 291 
National Eye Research Centre, Above and Beyond and Moorfields Eye Charity supported by 292 
infrastructural investment from the National Institute for Health Research. The sponsor and 293 
funders had no role in the study design, in the collection, analysis, and interpretation of data, 294 
in the writing of the report or in the decision to submit the paper for publication. In addition, 295 
the corresponding author had full access to all of the data and the final responsibility to 296 
submit for publication. (PNT RH CMD and RL had access to the raw data). 297 
 298 
Results 299 
Study Population 300 
126 people were recruited and randomised in this study between February 2006 and October 301 
2013 (71 patients from Moorfields Eye Hospital, 34 from Bristol Eye Hospital, 7 from 302 
Manchester Eye Hospital, 5 from the Western Eye Hospital, 4 from University College 303 
London Hospital, 4 from Gartnavel General Hospital and 1 from the University Hospital of 304 
Wales).  The flow of study participants is shown in Figure 1.  Data on both the primary 305 
outcomes at 48 weeks was provided by 101103 participants, and these were analysed after 306 
data-lock (which included separate 3 year assessments on a minority of trial subjects) on 7
th
 307 
October 2016. Baseline characteristics of the minimisation variables by group are shown in 308 
Table 1. Individuals allocated to azathioprine had a relatively lower proportion of non-309 
caucasianCaucasian patients (not a criterion used for minimisation).  310 
 311 
Intention-to-treat (ITT) analysis 312 
Binary Clinical Composite Outcome (BCCOM)Measure (primary outcome) 313 
The difference in BCCOMthe binary clinical composite outcome measure  between 314 
individuals randomised to azathioprine versus placebo tablets was on the threshold of our 315 
pre-specified significant p-value of <0.05, but did not meet this (the adjusted  odds ratio 316 
[ORadj] OR(adj) of BCCOMthe binary clinical composite outcome measure’s improvement on 317 
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azathioprine was 2·56; 95%CI 0·98, 6·66; p=0·05, Table 2 Figure 2A). In contrast , there 318 
was no indication of improvement with orbital radiotherapy (OR(adj) =0·89, 95%CI 0·36, 319 
2·23, p=0·80). WithAlso, with regard to the factorial design, there was no evidence of 320 
interaction between azathioprine and radiotherapy (pint = 0·86) and the combination of 321 
azathioprine and orbital radiotherapy did not offer additional advantage over azathioprine 322 
alone. An overview of the impact on BCCOM of the binary clinical composite outcome 323 
measure of azathioprine and orbital radiotherapy is shown in Supplementary Figure 324 
2A+2B. Furthermore, additional sensitivity analyses in which withdrawn patients were coded 325 
to unfavourable BCCOM outcomes regardless of their status at 48 weeks enhanced rather 326 
than lessened the improvement observed with azathioprine treatment (ORadjOR(adj) 3·65; 327 
95%CI 1·34, 9·86; p=0·01,) ( Supplementary Table 4). 328 
 329 
Ophthalmopathy Index (OI) (primary outcome) 330 
Analysis of all patients revealed that the OIophthalmopathy index fell between week 12 331 
(mean 9.15, SD 0.39)  and week 48 (mean 8.43,  SD 0.38, p=0.04). No additional benefits 332 
were seen with either azathioprine or orbital radiotherapy. Individuals randomised to 333 
azathioprine had an adjusted Beta (B)(adj) of 0·46 (95%CI -1·04, 1·95; p=0·55) and in those 334 
randomised to orbital radiotherapy B(adj) was -0·89 (95%CI -2·34, 0·56; p=0·23) (Table 2). 335 
There was also no evidence of an interaction between azathioprine and radiotherapy in their 336 
effect on OIophthalmopathy index (pint = 0·51). 337 
 338 
Clinical Activity Score (CAS) (co-primary outcome) 339 
Across all subjects, substantial improvement in median CASclinical activity score was seen 340 
over the study period from 5 (IQR 4 - 5) at baseline to 3 (IQR 2- 4; p<0·0001) at week 12, 341 
and 2 (IQR 1-3; p<0·0001) at week 48 (Figure 2B, 2C). The majority of patients n=97 342 
(70·0%) improved their CAS clinical activity score by week 12 and 96 (98%) of the 98 343 
patients with CASclinical activity score data at 48 weeks showed improvement in their 344 
CASclinical activity score versus baseline. No differencesdifference in the change in 345 
CASclinical activity score at 12 weeks werewas observed between individuals who received 346 
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treatment with azathioprine versus not receiving azathioprine, or who received radiotherapy 347 
versus sham radiotherapy B(adj)= -0·01 (95%CI -0·69, 0·68; p=0·99 – Table 2). There was no 348 
evidence of interaction between azathioprine and radiotherapy in their effect on CASclinical 349 
activity score (pint= 0·48). There was also no evidence for substantial benefit fromthat 350 
azathioprine or orbital radiotherapy on improving CASimproved clinical activity score  at 351 
week 48 (Supplementary Table 5).  352 
  353 
ThyroidTotal Eye Score (TES) (secondary outcome) 354 
TESTotal Eye Score improved considerably over the study period with a mean TES at 355 
baseline of 15·1 (95%CI 13·8, 16·3) falling to a mean TES of 9·36 (95%CI 8·12, 10·6; p 356 
<0·0001), but this was not affected by the addition of either azathioprine or orbital 357 
radiotherapy (Supplementary Table 6).  358 
 359 
Graves OpthalmopathyOphthalmopathy Quality of Life (GO-QoL) (secondary outcome) 360 
Across all subjects, mean GO-QoLGraves ophthalmopathy quality of life visual function was 361 
higher (improved) at 12 weeks than at baseline (71·5 - 95%CI 66·1, 76·9 vs 64·1 - 95%CI 362 
58·5, 70·0; p=0·002), and at week 48 (75·5 - 95%CI 70·3, 80·7; p<0·001 versus baseline). 363 
GO-QoLGraves ophthalmopathy quality of life visual appearance was also higher at 12 364 
weeks than at baseline (58·0 - 95%CI 52·5, 63·5 vs 53·2 - 95%CI 47·9, 58·6;  p=0·007) and 365 
at week 48 (61·3 - 95%CI 55·6, 67·1; p=0·001 versus baseline). Individuals who had an 366 
improvement in the BCCOM outcomebinary clinical composite measure at week 48 had a 367 
higher GO-QoLGraves ophthalmopathy quality of life visual function (B=17·9 - 95%CI 7·07, 368 
28·6; p<0·001) and a higher GO-QoLGraves ophthalmopathy quality of life visual 369 
appearance (B(adj)=11·5 - 95%CI 0·60, 23·6; p=0·06). There was no clear benefit from the 370 
addition of either azathioprine or orbital radtiotherapyradiotherapy with regard to long-term 371 
GO-QoLGraves ophthalmopathy quality of life visual function  or visual 372 
appearenceappearance (Supplementary Table 7, Supplementary Figure 3).   373 
 374 
As-per-protocol (APP) analysis 375 
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Sixty individuals did not withdraw from study treatment before 48 weeks, completed their 376 
therapy period as allocated and were included in the APPas-per-protocol analysis. Ten of 377 
these patients were randomised to azathioprine and sham-radiotherapy, 17 were randomised 378 
to orbital radiotherapy and placebo alone, 12 were randomised  to azathioprine and orbital 379 
radiotherapy and 21 were randomised to sham-radiothearpyradiotherapy and placebo. 380 
Individuals in the APPas-per-protocol analysis appeared similar at baseline to those who 381 
were withdrawn from study treatment, although there was a higher percentage of non-382 
caucasiansCaucasians in those recruited from the larger study centres (Supplementary Table 383 
8). 384 
 385 
In the APPas-per-protocol analysis, individuals randomised to receive azathioprine (n=22) 386 
had a higher odds ratio of improvement in their disease severity measured by the primary 387 
binary clinical composite outcome BCCOMmeasure at 48 weeks (OR(adj)=6·83, 95%CI 1·66, 388 
28·1; p=0·008). No benefit was seen in individuals randomised to receive orbital 389 
radiotherapy  (OR(adj) 1·32, 95%CI 0·36, 4·84; p=0·67, Table 3 Figure 2A).  To assess the 390 
effect of the duration of exposure to azathioprine we also conducted a comparative analysis 391 
of pateintspatients who continued to receive their allocated treatments at 12 weeks (n=84), 24 392 
weeks (n= 79) and 36 weeks (n=68). This indicated that benefit was observed with ≥24 393 
weeks of azathioprine exposure (Figure 2A, Supplementary Table 49 and Supplementary 394 
Figure 2A). Individuals receiving azathioprine also had a modest improvement in  TEStotal 395 
eye score (B(adj)= -3·23, 95%CI -6·42, 0·03; p=0·05, Supplementary Table 6). However, the 396 
APPas-per-protocol analysis did not reveal any benefit in OI, CASophthalmopathy index, 397 
clinical activity score or GO-QoLGraves ophthalmopathy quality of life of being randomised 398 
to receive either azathioprine or orbital radiotherapy (Table 3).  399 
 400 
Withdrawals from the study  401 
In the study thereThere was a high number of patients who withdrew from there allocated 402 
treatment (n=66, 52·4%) (Figure 1), but the majority of these (n=45, 68.2%) returned for 403 
primary outcome evaluation. Twenty-five withdrawals were within the first 12 weeks 404 
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(Figure 3). Withdrawals were less in non-caucasiansCaucasians and in participants at two of 405 
the study centres (Moorfields and Bristol Eye Hospitals). Before 48 weeks there were 40 406 
withdrawals in those randomised to receive azathiporineazathioprine and 34 407 
withdrawlswithdrawals in those randomised to receive orbital radiotherapy. Overall, 103 408 
participants provided outcome data, of which 84 completed their allocated treatment of  409 
radiotherapy or sham-radiotherapy, and 57 continued to take azathioprine or placebo until 48 410 
weeks.  Participants randomised to receive azathioprine had increased odds of withdrawal 411 
compared to those who did not OR(adj)=2·82 (95%CI 1·23, 6·45) p=0·01 (Supplementary 412 
Table 910). The reasons for withdrawal are presented in Supplementary Figure 4. Patients 413 
receiving azathioprine had an increased odds of withdrawal due to precautionary blood test 414 
abnormalities or side effects OR=9·10 (95%CI 2·60, 31·9) p=0.001 (Supplementary Table 415 
1011). However, unlike patients receiveingreceiving placebo, patients taking azathioprine did 416 
not withdraw due to deterioration following cessation of steroid treatment at 24 weeks 417 
(Figure 3C).  No baseline characteristics predicted withdrawal due to either azathioprine or 418 
orbital radiotherapy although the highest odds of withdrawal for disease deterioration was in 419 
the sham-radiotherapy and placebo group (Supplementary Table 1112). There was no 420 
evidence of bias between treatment groups with regard to failure to provide data at 48 weeks 421 
(Supplementary Table 1213 and Supplementary Table 1314). 422 
 423 
Rescue therapy (including surgery) and adverse events 424 
Twenty-one (47%) of the trial subjects who withdrew from study treatment but provided 425 
outcome data were documented to have received additional therapy (Supplementary Table 426 
1415). In most cases this was additional steroid therapy continuing until the endpoint of the 427 
study (week 48). Surgery was however required in 5 individuals, 3 of whom were in the 428 
azathioprine group (3 orbital decompressions, 1 lid surgery and 1 strabismus correction).  The 429 
number of individuals experiencing an adverse event did not differ across the treatment 430 
groups (azathioprine N=161, radiotherapy N=156). (Supplementary Table 1516 and 431 
Supplementary Table 1617).  432 
 433 
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Masking 434 
Of the 69 patients and 71 doctors who recorded their perceived trial allocation for 435 
azathioprine or placebo on study completion or withdrawal, 30 patients (43%) and 29 doctors 436 
(41%) were incorrect. For radiotherapy and sham-radiotherapy, of the 70 patients and 67 437 
doctors, 23 patients (33%)  and 33 doctors (49%) were incorrect. 438 
 439 
Discussion 440 
CIRTED fulfilled its target sample size, with more than 100 complete data sets at 48 weeks. 441 
Improvement in our primary, co-primary and secondary outcome measures (BCCOM, CAS 442 
and GO-QoLbinary clinical composite outcome measure, clinical activity score and Graves 443 
ophthalmopathy quality-of- life score) across all groups confirmed the previously reported 444 
benefits of high dose systemic corticosteroid therapy in active moderate-to-severe thyroid eye 445 
disease  (Figures 2B and 2C). In this context, orbital radiotherapy did not confer additional 446 
patient benefit in any pre-specified outcome measure either in the short (12-week) or longer 447 
term (48-week). Since radiotherapyRadiotherapy was delivered early in the treatment (before 448 
12 weeks),); hence it is unlikely that this result is significantly confounded by the high 449 
withdrawal rate later in the treatment course.  450 
 451 
Less strong conclusions can be drawn with regard to azathioprine as comparatively few 452 
patients completed the full course of treatment. Nonetheless, the improvement in BCCOMthe 453 
binary clinical composite outcome measure observed in the azathioprine-treated group of 454 
subjects that was on the threshold of statistical significance in our intention-to-treat analysis 455 
(p=0.05) is likely to be real as the effect was sustained or enhanced in our sensitivity analyses 456 
(Supplementary Table 4, Supplementary Table 49). This is reinforced by the APPpost-hoc 457 
as-per-protocol analysis results which showed substantial benefit in favour of azathioprine 458 
(OR(adj)=6·83 p=0·008).  Of note, patient outcomes improved particularly in those receiving 459 
azathioprine for 24 weeks or more (figure 3A). Since steroid therapy was stopped at 24 460 
weeks (as is common practice in TEDthyroid eye disease), this suggests that the key benefit 461 
of azathioprine is to prevent relapse after withdrawal of steroids. This observation is 462 
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consistent with the generally recognsiedrecognised role of azathioprine as a steroid-sparing 463 
agent, used to prevent relapse in other autoimmune conditions., and this is further reinforced 464 
by the findings of the MINGO study using an alternative antiproliferative agent 465 
(mycophenolate sodium) in thyroid eye disease. Furthermore, this view is supported by 466 
analysis of the BCCOMbinary clinical composite outcome measure components indicating 467 
that azathioprine did not increase major improvement rates overall but did reduce major 468 
deterioration in the BCCOMbinary clinical composite outcome measure (p=0.004, 469 
Supplementary Figure 2A), plus the observation that late withdrawal (after 24 weeks) due 470 
to deterioration was not seen in patients treated with azathiorineazathioprine (Figure 3C).  471 
 472 
A major feature of this study was the high rate of withdrawal from patients’ allocated 473 
treatment. In all study groups, early withdrawals (before 24 weeks) due to disease 474 
deterioration were seen as the steroid dose was reduced. and this was not mitigated by orbital 475 
radiotherapy (Figure 3C). Our masked protocol necessarily set strict thresholds for 476 
withdrawal due to abnormal monitoring blood tests (white cell counts and liver function), 477 
which together with treatment side-effects led to more common withdrawals in those 478 
allocated to azathioprine (Figure 3B). Hence, it is likely that in usual clinical practice 479 
azathioprine treatment would be continued in a higher percentage of patients.  Importantly, 480 
many of those withdrawing from treatment still completed their study follow-up visits until 481 
the primary endpoint (48 weeks), resulting in the outcomes for over 80% of randomised 482 
subjects being available for the ITTour intention-to-treat analysis. 483 
 484 
The other key methodological point to consider is our use of two primary outcome measures 485 
at 48 weeks. As we have previously published
26
, this was because of the lack of fully 486 
validated long-term disease severity measures in TED. (26), this was because of the lack of 487 
fully validated long-term disease severity measures in thyroid eye disease. We also wished to 488 
mitigate the theoretical limitations of composite binary scoring systems, in particular with 489 
regard to baseline variability between treatment groups, by using a continuous variable with 490 
regression analyses in mind. However, our minimisation strategy was successful in balancing 491 
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baseline features across trial arms and the BCCOMbinary clinical composite outcome 492 
measure has since become the preferred end-point for TEDthyroid eye disease studies as it is 493 
more sensitive to change(21, 23). We have therefore focused on this rather than the 494 
OIophthalmopathy index which has not been a primary endpoint in other recent trials.  495 
 496 
The key strengths of this RCT include the use of minimisation, low rates of loss-to-follow-up 497 
(including of withdrawn patients) and the success of our extensive efforts that were made to 498 
mask both azathioprine and radiotherapy treatment allocation to both the patients and 499 
clinicians. (including the use of sham radiotherapy). In addition, we observed no evidence of 500 
interaction between the two interventions (radiotherapy and azathioprine), which is 501 
supportive of our choice of a factorial design. Conversely, a major limitation of our study was 502 
the high withdrawal rate, particularly for those randomised to receive azathioprine. 503 
Therefore, our conclusions with regard to the efficacy of this treatment need to be interpreted 504 
with caution. We also permitted patients to enrol in the trial and start systemic corticosteroid 505 
therapy before their thyroid function tests were normalised. This potentially confounds the 506 
interpretation of our data with the benefit of returning to euthyroidism, but we judged 507 
intervening with immunosuppression in the early active phase of disease to outweigh this 508 
risk. Furthermore, given that demonstration of clinical improvement following a 2 -week 509 
course of high-dose oral steroids was a key entry criterion, our results cannot be extrapolated 510 
to infer the value of radiotherapy or azathioprine in patients with steroid refractory disease. 511 
Oral corticosteroid therapy was used in this study and given to all study participants as this 512 
was the standard of care in the study centres at the time of trial initiation and remains 513 
commonly prescribed in many regions of the world including North America (29).  514 
 515 
In summary, our results suggest that low-dose orbital radiotherapy confers no additional short 516 
or long-term treatment benefit when combined with a six-month reducing course of oral 517 
corticosteroids. Our findings with regard to azathioprine are less definitive, but taken together 518 
they indicate that, if tolerated, azathioprine improves 48-week clinical outcomes in patients 519 
with active moderate-to-severe TED.thyroid eye disease. This supports the use of long-term 520 
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antiproliferative treatments in combination with systemic corticosteroids for the treatment of 521 
active moderate-to-severe TEDthyroid eye disease, consistent with established practice in 522 
other autoimmune conditions.   523 
 524 
 525 
 526 
  527 
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2 BACKGROUND INFORMATION 
Thyroid Eye Disease (TED) is an inflammatory autoimmune condition of the orbit 
which is clinically apparent in 25-50% of people with Graves‟ hyperthyroidism1. The 
majority of patients report only mild symptoms, but 5% of the UK‟s 400 0002 TED 
sufferers (many of them young women in the age group 20-50) have severe TED, 
characterised by swollen eyelids, protrusion of the eyes (proptosis) and double vision 
(diplopia). 
2.1 Pathophysiology 
The key pathological features of TED are orbital inflammation, orbital fat proliferation 
and extra-ocular muscle enlargement. The size of the bony space to accommodate 
these expanding tissues is fixed, causing the intra-orbital pressure to rise and the 
globe to proptose forward. Rising orbital pressure also alters the local circulation of 
lymph and blood: outflow is obstructed while inflow continues, and a vicious cycle of 
further tissue engorgement ensues3. In extreme cases this leads to optic nerve 
compression and results in loss of vision. Individuals with tight eyelid ligaments, who 
are unable to “autodecompress” by proptosis, are at particular risk of this. 
The exact pathogenesis of TED is uncertain, but it is known to be an autoimmune 
process caused by cross-reactivity between proteins in the orbit and thyroid gland3. 
Its natural history is classically described in three phases; an initial „active‟ 
inflammatory phase, a subsequent regressing phase, and (after 1 – 3 years) a final 
„inactive‟ („burnt out‟) phase4. Recovery is variable, and the residual disfigurement 
and visual disability is permanent. Unlike most other autoimmune diseases, TED 
rarely reactivates5.  
2.2 Treatment 
There is great controversy about the best treatment for TED. Traditionally, it was 
managed conservatively during the inflammatory phase, and the residual deformity 
was then corrected surgically (including orbital decompression, strabismus correction 
and eyelid repositioning) when the disease had burnt out. In addition to the surgical 
burden for patients and ophthalmologists, this approach did not address the 
underlying pathology and outcomes were frequently imperfect. 
Systemic immunosuppression and radiotherapy, directed at the initial inflammatory 
response in the active phase of the disease, might be expected to modify the 
subsequent disease course and reduce the severity of residual orbital fibrosis; 
thereby improving long-term function and reducing the need for rehabilitative surgery. 
However, confusion has arisen over the role of these treatments for the following 
reasons: 
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1. Limitations in the quality of evidence: 
a. The majority of previous reports on radiotherapy in TED are 
retrospective and / or uncontrolled. 
b. Most studies have involved small sample sizes. 
c. Few trials have evaluated long-term results (1 year or more) 
d. Several studies have not distinguished between inactive and active 
disease in their analysis of treatment outcome. 
2. Recent randomised controlled trials on radiotherapy in TED have produced 
conflicting results. 
3. Concern about the side-effects caused by systemic immunosuppressants. 
2.3 Review of the Literature - the Need for a Trial 
2.3.1 Glucocorticoids and Ciclosporin 
Several studies have shown that glucocorticoids are effective in the management of 
severe TED6 7. However, treatment is typically discontinued after 3 to 5 months8-11 
because of the side-effects associated with long-term steroid use, and subsequent 
disease reactivation is a common problem7. This recurrence can be prevented by the 
concomitant use of ciclosporin (which continues after steroid treatment stops)12, and 
combinations of ciclosporin and prednisolone also achieve a better initial treatment 
response than either agent alone8. However, the routine use of such second-line 
immunosuppressive drugs in the management of severe TED has been limited by 
fears about their potential toxicity, and glucocorticoid monotherapy remains the 
mainstay of conventional treatment. 
2.3.2 Orbital Radiotherapy 
Radiotherapy has been used to treat TED for more than 60 years, and until recently it 
had an established place in the management of the disease13 14. Its use was 
supported by the results of a prospective blind randomised control trial (RCT) which 
reported (in 1993) that orbital radiotherapy was as effective as oral prednisolone15. 
However, the same authors subsequently found that radiotherapy was no better than 
placebo (except in a subgroup of patients with motility impairment)16, and a recent 
trial from the Mayo Clinic in the USA also could not demonstrate a beneficial 
therapeutic effect17. As a result, many clinicians, particularly in North America, have 
abandoned its use.  
The Mayo study has been widely criticised, and European groups argue that the 
balance of evidence remains in favour of radiotherapy18. In support of this, the most 
recent randomised control trial (in patients with relatively mild disease) found that 
radiotherapy was better than placebo when outcome was assessed by clinical 
measures19. However, this was not associated with quality-of-life or health economic 
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gain, and the role of radiotherapy as monotherapy for TED remains the subject of 
heated debate20-29.   
Older RCTs have shown that radiotherapy is more effective in combination with 
steroids than when either agent is used alone30 31. However, this distinction between 
monotherapy and combination therapy is rarely highlighted, and the confusion which 
has resulted from the inconsistent recent evidence has caused many 
ophthalmologists to abandon radiotherapy as part of a combined treatment regime. 
Consequently there is an urgent need for a definitive study to establish radiotherapy‟s 
role in combination with steroids. 
2.3.3 Combined Immunosuppression and Azathioprine 
The data supporting the use of ciclosporin combined with steroids8 12, and 
radiotherapy combined with steroids30 31 are not surprising given current knowledge 
about the benefits of combination therapies in other autoimmune ocular and systemic 
conditions (such as uveitis and rheumatoid arthritis)32 33. Manipulation of an 
autoimmune response is more effective when more than one mechanism of 
immunosuppression is used, and this can be especially so early in the disease32. 
Each drug can also often be given in a lower dose than with monotherapy, improving 
safety. Combined drug treatments can also be continued long-term, preventing the 
disease reactivation which is commonly seen at the end of typical short-term steroid 
monotherapy regimes, and enabling the duration of an individual‟s treatment to be 
tailored to the length of their disease. 
Azathioprine is a low-cost second-line immunosuppressive agent which is commonly 
used in the management of other autoimmune conditions. It is better tolerated than 
ciclosporin34 and does not cause the renal toxicity and cardiovascular side-effects35 
(including hypertension and hypercholesterolaemia) associated with ciclosporin. 
However, it can cause bone marrow suppression36 and hepatotoxicity37. This risk has 
been greatly reduced with the advent of a new laboratory assay for the enzyme 
thiopurine methyltransferase (TPMT), which regulates a key step in azathioprine 
metabolism. Now individuals with low TPMT activity, who would otherwise be at 
particular risk of azathioprine toxicity, can be identified and their treatment modified 
or withheld38. Hence, azathioprine has safety and tolerability advantages over 
ciclosporin. 
Retrospective data from Bristol Eye Hospital suggests that azathioprine, when used 
in combination with oral prednisolone and radiotherapy, can significantly reduce long-
term TED severity and the need for rehabilitative surgery39. A recent publication from 
the Royal College of Ophthalmologists has recommended this regime40, however the 
use of azathioprine for TED remains highly controversial; in part because it has 
previously been proven ineffective as monotherapy41. As with radiotherapy, there is 
no clear evidence base and clinical practice consequently varies widely.  
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2.4 Trial Summary 
This randomised controlled trial of azathioprine and radiotherapy (with prednisolone) 
will be the first to establish the role of these interventions as part of a long-term, 
combination immunosuppressive treatment regime for TED. Such a definitive study is 
required to resolve the debate which currently surrounds these treatments and to 
provide evidence for authoritative management guidelines. Only patients with active 
orbital inflammation will be enrolled and follow-up will continue for a minimum of 1 
year. A factorial design is used to allow the efficacy of both interventions to be 
assessed in a single study with efficient use of patients; and the establishment of a 
multi-centre network of trial sites will ensure adequate patient numbers for statistical 
power. Health economic and carefully designed quality of life/disfigurement analyses 
in collaboration with the Division of Primary Care (University of Bristol) and the 
Centre for Appearance Research (University of West of England) will accompany the 
trial. 
2.5 Trial Publications 
R Rajendram, RWJ Lee, MJ Potts, GE Rose, R Jain, JM Olver, F Bremner, S Hurel, 
A Cook, R Gattamaneni, M Tomlinson, N Plowman, C Bunce, SP Hollinghurst, L 
Kingston, S Jackson, AD Dick, N Rumsey, OC Morris, CM Dayan, JM Uddin. (2008) 
Protocol for the Combined Immunosuppression & Radiotherapy in Thyroid Eye 
Disease (CIRTED) Trial: a multi-centre, double-masked, factorial randomised 
controlled trial. Trials 2008, 9:6 doi:10.1186/1745-6215-9-6 
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3 OBJECTIVES 
3.1 Primary 
Test the hypotheses that in patients being treated with prednisolone for active TED: 
 
1. RADIOTHERAPY (compared with placebo) induces early remission and 
reduces long-term disease severity. 
 
2. COMBINED SYSTEMIC IMMUNOSUPPRESSION WITH ORAL 
AZATHIOPRINE (compared with placebo) reduces long-term disease 
severity. 
3.2 Secondary 
1. To test the hypotheses that in patients being treated with prednisolone for 
active TED, radiotherapy and azathioprine improve health-related quality 
of life, and are cost-effective. 
 
2. To validate the use of the GO-QoL (a new TED specific quality of life 
score)42 in the UK population. 
 
3. To improve understanding of the extent and type of psychosocial distress 
experienced by TED patients. 
 
4. To conduct an economic evaluation of the cost of TED and its treatment to 
patients, the National Health Service (NHS) and Society. 
 
5. To report the safety and tolerability of radiotherapy and azathioprine in the 
study cohort. 
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4 TRIAL DESIGN 
4.1 Factorial Design 
Factorial randomised trials allow two interventions to be evaluated in a single study. 
This has particular advantages for the assessment of combined treatment regimes, 
especially when considering relatively uncommon conditions with a limited number of 
potential recruits43 44, such as TED. They are the most valid means of establishing 
whether the combination of two or more therapies achieves incremental benefits43. 
4.1.1 Application to CIRTED. 
 
TRIAL ARMS
ACTIVE TED
RADIOTHERAPY + 
AZATHIOPRINE
RADIOTHERAPY + 
PLACEBO
SHAM –RADIOTHERAPY
+ PLACEBO
ALL PATIENTS RECEIVE A STANDARD 
STEROID REGIME
R
A
N
D
O
M
I
Z
E
SHAM – RADIOTHERAPY 
+ AZATHIOPRINE
 
 
Trial participants will be separately randomised to receive radiotherapy or sham-
radiotherapy, and azathioprine or placebo (illustrated above).  
4.1.2 Discussion of the Risks Associated with a Factorial Design 
When factorial design is used in the analysis of very large samples it can determine 
the interaction between interventions. For example, to assess whether the effect of 
Treatment A plus Treatment B is greater (or less) than the sum of Treatment A‟s 
effect alone and Treatment B‟s effect alone. This can give special insight into the 
benefits, or otherwise, of multiple therapies. However, if the two interventions under 
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consideration interact, and the sample size is too small to reveal this interaction, their 
calculated independent effects may be incorrect. Hence, when using factorial design 
to establish the effect attributable to individual components of a combination 
treatment regime it is important to be sure there is no significant interaction between 
interventions43. 
In CIRTED the sample size will not be large enough to draw any meaningful 
conclusions about the degree of interaction between treatments, as the confidence 
intervals from this analysis will be too large. Consequently we have assessed the risk 
of potential 'biological interactions' and 'statistical interactions' which might lead to 
erroneous results in the analysis of individual treatment effects. 
Radiotherapy and azathioprine are both thought to reduce the inflammatory response 
in TED through their effects on T-lymphocytes in the orbit, but each works by an 
entirely different biological mechanism. Their common goal of reducing the T-
lymphocyte response means that they are subject to the 'law of diminishing returns'. 
That is, once the T-lymphocytes have been 'hit' by radiotherapy there will be a limit to 
the further suppression which can be achieved with the addition of azathioprine. 
However, we would not expect radiotherapy to affect the mechanism by which 
azathioprine works, and in this sense they should not 'interact'. 
Taking all the above into account, the statisticians who have advised on the CIRTED 
trial consider the potential for an interaction between our interventions having a 
'clinically significant' effect on the interpretation of the trial data is very low 
(approximately 5%), and factorial randomisation has been recommended as the most 
appropriate trial design. 
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4.1.3 Principles of Analysis 
The following table is an alternative representation of the treatment groups in 
CIRTED which can be used to illustrate the method of factorial trial analysis. 
 
SHAM –
RADIOTHERAPY + 
PLACEBO
RADIOTHERAPY
+ 
PLACEBO
SHAM –
RADIOTHERAPY 
+ AZATHIOPRINE
RADIOTHERAPY
+ 
AZATHIOPRINE
 
 
Factorial analyses can be conducted „inside the table‟ or „at the margins‟. Both will be 
calculated, but the examination of the interaction between the effects of azathioprine 
and radiotherapy „inside the table‟ will be imprecise with our sample size. 
The effects of radiotherapy and azathioprine will be determined separately by 
combining and comparing the cells of the table „at the margins‟ as illustrated overleaf: 
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RADIOTHERAPY vs SHAM-RADIOTHERAPY 
Treatment response will be compared between patients receiving either radiotherapy 
plus azathioprine or radiotherapy plus placebo WITH patients receiving either sham-
radiotherapy plus azathioprine or sham-radiotherapy plus placebo. 
 
SHAM –
RADIOTHERAPY + 
PLACEBO
RADIOTHERAPY
+ 
PLACEBO
SHAM –
RADIOTHERAPY 
+ AZATHIOPRINE
RADIOTHERAPY
+ 
AZATHIOPRINE
 
 
AZATHIOPRINE vs PLACEBO 
Treatment response will be compared between patients receiving either azathioprine 
plus radiotherapy or azathioprine plus sham-radiotherapy WITH patients receiving 
either placebo plus radiotherapy or placebo plus sham-radiotherapy. 
 
 
SHAM  – 
RADIOTHERAPY +  
PLACEBO 
RADIOTHERAPY 
+  
PLACEBO 
SHAM  – 
RADIOTHERAPY  
+ AZATHIOPRINE 
RADIOTHERAPY 
+  
AZATHIOPRINE 
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4.2  Minimizing Bias 
4.2.1 Treatment allocation 
Allocation of patients to the 4 arms of the study will be done using minimisation. This 
is a process that allocates patients based on (a) their own characteristics, and (b) the 
allocations of patients with the same characteristics already in the trial. The process 
gains its name by minimising the imbalance in numbers in each of the trial arms with 
respect to a range of important prognostic variables simultaneously. It is a dynamic 
process and a randomisation schedule is therefore not drawn up in advance. The 
variables used to minimise patients are:  
• Smoker at time of TED diagnosis (Y/N) 
• Thyroid status on enrolment (hyperthyroid / hypothyroid / euthyroid) 
• Previous Steroid use - defined as ≥ 20mg prednisolone for ≥ 1 month in the 
previous 6 months (Y/N) 
• Gender (M/F) 
• Disease severity (Total Eye Score < 22 / Total Eye Score ≥ 22) 
• Study Centre  
• Disease Duration (<6 months / ≥ 6 months) 
• Age (< 60 yrs / ≥ 60 yrs) 
• Disease Activity (Clinical Activity Score 2 – 3 / 4 – 5 /  6 – 7) 
 
The 4 trial arms to which minimisation will be applied in this study are: (A) sham-
radiotherapy and azathioprine (B) radiotherapy and azathioprine (C) sham-
radiotherapy and placebo, and (D) radiotherapy and placebo. 
The Trial pharmacists at each study centre, who are unmasked, will contact the 
Telephone Randomisation Service provided by Moorfields Eye Hospital Clinical Trials 
Unit to obtain the treatment allocation for each recruit. This is confirmed by email, 
which also states the patient's radiotherapy group – a copy of which is sent to the 
Trial Radiotherapy Centre radiographers and the un-masked trial co-ordinator. 
 
4.2.2 Masking 
Masked individuals: 
1. Patients 
2. Clinical Investigators (Ophthalmologists, Research orthoptists, Masked 
research nurses, Psychosocial investigators, Health economic analysts and 
clinical oncologists) 
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3. Data Analysts 
 
Un-masked individuals: 
1. Unmasked trial co-ordinators and research nurses (responsible for reviewing 
blood tests to monitor for azathioprine related adverse events) 
2. Trial Pharmacists 
3. Radiographers 
4. Ophthalmic Clinical Investigators will be masked to the treatments received 
by patients in their own Centre, but they may be un-masked to the treatment 
group  the patients in the other Centre in order to give medical advice on the 
appropriate action following abnormal blood test results or to give prescribing 
instructions 
Patients and the ophthalmic / endocrine teams responsible for their care, will be 
informed of their treatment allocation on trial exit or completion.    
4.2.3 Other Measures for Maintaining Masking and Protecting 
Against Bias 
All trial recruits, whether allocated to the azathioprine or placebo arms of the trial, will 
have regular blood tests to monitor for the potential adverse effects of azathioprine 
treatment; otherwise this would break masking for both the patient and investigators. 
Repeat Blood Tests and Azathioprine Dose Adjustment 
It is estimated that less than 5% of azathioprine treated trial subjects will have blood 
test abnormalities for which they will be recalled45. In order to maintain masking we 
also plan to randomly recall ≤5% of the placebo treated group. 
On recall, these trial subjects will have repeat blood tests and / or their drug dose 
adjusted. For azathioprine-treated patients this dose adjustment will be titrated to 
their blood test results. The dose range is 50mg – 200mg (ie 1 - 4 x 50mg 
Azathioprine tablets). Recalled placebo-treated patients will also have the number of 
tablets they take randomly changed (ie 1 - 4 x placebo). 
Standard Patient Assessments 
A standard „atlas‟ of disease severity measures will be used to reduce inter-observer 
error in patient assessment46  
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4.3 Determination Of Sample Size  
4.3.1 Primary and Co-Primary Outcome Measures 
There are two primary outcomes, a binary composite variable rating success or 
failure10 16 19 and the Ophthalmopathy Index47. Both will be measured at 12 months 
after randomisation: 
 Binary composite variable rating success or failure: Success rates in the 
placebo arms compared with the treated arms have been estimated to be 
60% and 87% based on figures available in the literature48 and allowing for a 
possible placebo effect.  A two group continuity corrected chi-squared test 
with a 0.050 two-sided significance level will have 80% power to detect the 
difference between a success rate in the placebo arm of 60% and success 
rate in the treated arm of 87% (odds ratio of 4.462) when the sample size in 
each group is 48.  It is therefore necessary for there to be around 100 
subjects in the final data set equally distributed to the 4 randomisation codes. 
However, the power of the study to detect clinically significant differences will 
improve with increasing numbers of subjects.  
 Ophthalmopathy Index: The power for continuous outcome measures is more 
favourable. A total sample size of 100 patients will yield 92% power to detect 
a difference of 2.7 in the Ophthalmic Index with two-sided 5% alpha, 
assuming a standard deviation of 3.3. 
 
The Clinical Activity Score49 measured at 3 months after randomisation is defined as 
a co-primary outcome. This outcome does not have the same status as the two 
primary outcomes, in that it is not considered as important as the primary outcomes 
in terms of influencing future clinical practice. However it is of greater interest and 
importance than the secondary outcome variables, and as such, the power of the trial 
to detect a clinically important difference is presented here. Assuming a standard 
deviation of between 1.2 and 2.0, a total sample of 100 patients will yield between 
71% and 99% to detect a difference of 1 point with 5% two-sided alpha.  
4.3.2 Secondary Outcome Measures 
 The Total Eye Score (TES)8 
 The Graves Ophthalmopathy Quality of Life Score (GO-QoL)42 50, a disease 
specific quality of life score 
4.3.3 Predicted Enrolment  
Extrapolating recruitment across all trial centres from Jan 2006 until May 2008 it 
would take until Dec 2012 to complete the trial (total 6yrs recruitment plus 1yr follow-
up). Hence, in order to hit our revised end date of Dec 2011 (see section 4.4) the 
number of trial centres has been increased.  
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4.3.3.1 Compliance and loss to follow-up 
Of the 42 patients enrolled in Gorman et al‟s sham-radiotherapy trial, only 2 did not 
complete the protocol; and of the 60 patients in Mourits et al‟s sham-radiotherapy 
study, only one did not complete the protocol. Prummel et al‟s trial of combined 
immunosuppression with cyclosporine and prednisolone in 36 patients also reported 
only one loss to follow-up. Consequently, compliance is expected to be excellent 
once patients are enrolled in the study.  
Using these figures as a basis for estimating recruitment and drop-out: 
 33% of these will choose not to take part in the study16; 
 11% of these will be excluded because of TPMT inactivity51; 
 10% of the azathioprine treated group will be intolerant of therapy, or suffer 
an adverse event necessitating withdrawal from the trial52;  
 5% will drop-out for other reasons. 
 
4.4 Timescales 
4.4.1 Proposed Trial Start  
January 2006 
4.4.2 Projected Trial Completion 
December 2011 
4.4.3 Trial Duration 
6 Years 
4.4.4 Duration of Each Patient’s Participation 
1 year (plus a single additional review 2 yrs after trial completion for patients 
participating in the optional long-term follow-up study) 
4.4.5 Frequency of Follow-up 
Trial subjects are seen and randomised (if eligible) 2 weeks after enrolment .Their 
treatment response and tolerance is then assessed 4 weeks later, just prior to 
starting radiotherapy / sham-radiotherapy (see section 6.1). The short-term outcome 
assessment is then conducted at week 12, and trial recruits are subsequently seen 3-
monthly until they exit the trial 11 months post-randomisation. Regular blood tests will 
also be required after randomisation to monitor the potential adverse effects of 
azathioprine treatment. Further reviews can be arranged at the trial centres for any 
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reason at the patient or investigators‟ request. In addition, study recruits will be 
invited to have an optional long-term outcome assessment 2yrs after completing the 
trial.  
4.5 Quality Control  
4.5.1 Accountability for Investigational Products 
 Active Azathioprine tablets are being sourced via the NHS.  
 St Thomas‟ Hospital NHS Trust‟s Drug Manufacturing Unit are producing 
matched placebo tablets. In addition, they are responsible for packaging both 
the active Azathioprine and its placebo as Investigational Medicinal Products 
for use in the trial.  
 (See Clinical Trials Authorisation for further details) 
4.5.2 Procedures for monitoring subject compliance 
 Tablets will be counted by the Trial Pharmacists at each visit. 
 The patient will be asked about treatment compliance by the Clinical 
Investigators at each trial visit. 
4.5.3 Site Monitoring 
This is the responsibility of the Trial Sponsor, who will have direct access to source 
data. 
4.6 Safety 
4.6.1 Data Monitoring Committee (DMC) – also see section 1.4.1 
4.6.1.1 Interim analyses 
No formal interim analyses are planned, although this may be requested by the DMC, 
who will meet every 12-18 months to review a masked report of trial progress and 
adverse events.   
4.6.1.2 Adverse Events 
Adverse Event reports will also be presented to the DMC (although it is unlikely that 
any new safety data on the trial interventions will be revealed. Radiotherapy has 
been used to treat TED and Azathioprine has been used as a systemic 
immunosuppressant for decades. 
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4.6.1.3 Procedures for breaking randomisation codes 
Randomisation codes may be broken prior to trial completion at the request of the 
DMC. 
Randomisation codes for individual patients may be broken for withdrawn subjects.  
4.6.1.4 Criteria for termination of the trial 
The trial will only be terminated if the p value of an interim analysis is smaller than 
0.0001, and a DMC meeting to review all the evidence decides that this is the best 
course of action to take. 
4.6.2 Trial Steering Committee – also see section 1.4.2 
The Trial Steering Committee will meet on a 12 – 18 monthly basis. Their principal 
responsibilities will be to: 
 
1. Review the protocol and comment on any major errors in the trial design that 
they feel would prevent it addressing the primary objectives. 
2. Review progress reports on the trial and provide advice if problems arise. 
3. Comment on protocol amendments. 
4. Ensure that any new information on the trial interventions which becomes 
available after the start of the trial is properly considered. 
5. Protect the interests of patients should safety issues arise (although this will 
primarily be the responsibility of the Data Monitoring Committee). 
 
5 SELECTION AND WITHDRAWAL OF SUBJECTS 
5.1 Selection 
5.1.1 Subject Inclusion Criteria 
1. Mourits' Clinical Activity Score ≥ 4 out of 7 (worst eye) and a history of 
proptosis* or motility restriction  
OR 
 Mourits‟ Clinical Activity Score 2 or 3 out of 7 (worst eye) with a history of 
proptosis* or motility restriction of less than 6 months duration 
2. Past or present history of abnormal Thyroid Gland Function  OR a clinical 
diagnosis of TED made and confirmed by ≥ 2 muscle involvement on CT or 
MRI scan 
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* Definition of proptosis = EITHER subjective unilateral proptosis confirmed by 
asymmetry in exophthalmometry of > 2mm OR subjective bilateral proptosis.  
 Definition of motility restriction = intermittent, inconstant or constant diplopia grade54 
5.1.2 Subject Exclusion Criteria 
 Age <20 or >75 yrs 
 Optic neuropathy 
 Pre-existing glaucoma with a characteristic optic disc appearance and 
associated visual field defect  
 Use of radioiodine within the last 3 months 
 Pre-existing Diabetes Mellitus (not simply steroid induced disease from recent 
therapy) 
 Previous adverse event associated with, or contraindication to, either 
prednisolone or azathioprine 
 Within 6/12 of pregnancy, women planning pregnancy  
 Lactation 
 Haemoglobin Concentration > 1 g/dl below the local laboratory's reference 
range 
 Platelet Count < 130 × 109/L 
 Total White Cell Count below the local laboratory's reference range 
 Abnormal Thiopurine Methyltransferase (TPMT) activity  
 Lymphocyte Count < 0.8 x 109 / L 
 Abnormal renal function  (estimated Glomerular Filtration Rate (eGFR) < 60 
ml/min/1.73 m2) 
 Abnormal liver function, specifically: bilirubin, alanine aminotransferase or 
alkaline phosphatase concentrations > 1.5× above the local laboratory's 
reference range (excluding Gilbert‟s syndrome*)  
 Malignant or pre-malignant (dysplastic) condition within the past 5 years 
 Previous tuberculosis 
 Shingles within the past 3/12 
 HIV / AIDS 
 Concurrent use of  
o other immunosuppressive or cytotoxic agents 
o allopurinol 
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 Live vaccines within the past 3 months 
 Previous orbital irradiation 
NB Trial subjects with a disease duration of > 6 months who do not improve with 
steroid treatment in the first 2 weeks post enrolment will withdraw from the trial and 
not be randomised (see section 5.3.1 Exit Criteria) 
 
*Gilbert‟s syndrome is a common hereditary, harmless cause of raised bilirubin which 
is not a contraindication to azathioprine treatment. 
 
5.2 Recruitment and Identification of Eligible subjects 
5.2.1 Advertising 
The CIRTED trial will be formally announced at academic and professional meetings 
to encourage referral of eligible patients to the Trial Centres. Literature publicising the 
trial will also be circulated to Ophthalmologists in the region of each Trial Centre and 
a website for health-care professionals and patients to access information about the 
trial has been set up (www.cirted.org). The trial protocol has also been published 
(see section 2.5) 
Patient groups are already aware of this study and a summary of the trial‟s goals and 
structure has been presented at meetings of the Thyroid Eye Disease Charitable 
Trust (TEDct). An introduction to the trial has also been published in the TEDct 
newsletter. 
5.2.2 Screening 
Identification of Trial Subjects and Pre-visit Screening  
All referral letters to the Trial Centres for patients with active Thyroid Eye Disease will 
be reviewed by the Investigators.  
Contacting Patients 
Who are already aware of the Trial (ie they have been specifically referred for the 
study) 
Patients specifically referred for trial screening are contacted by phone to arrange an 
appointment. Their patient information is then sent out by email or post (whichever 
they prefer). 
Who are unaware of the Trial, and have just been referred for assessment of their 
TED 
Patients who are potentially suitable for the trial are contacted by letter and sent a 
Patient Information Sheet prior to their out-patient appointment. If the patient returns 
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the study reply slip they will be phoned by a member of the research team to check 
their eligibility. This phone call will: 
 Explain that the Eye Hospital / Clinic to which the patient has been 
referred for specialist management of their TED is involved in a research 
study to investigate the best treatment for this condition, and that all new 
referrals are being assessed for their eligibility to participate. 
 Highlight that there is no expectation or requirement that the patient will 
take part in the clinical trial. 
 Clarify whether the patient is potentially eligible to participate 
 Offer the opportunity to answer any questions they may have about the 
study after reading the patient information sheet or website. 
Contacting the Patient’s General Practitioner, Endocrinologist or Local 
Biochemistry Laboratory 
If required, this will be done to clarify: 
 The results of all Thyroid Function Tests within the past 3 months. 
5.2.3 Clinical Assessment of New Referrals and Trial Enrolment 
Potentially eligible patients will be assessed by one of the Clinical Investigators. If 
this consultation is in a NHS out-patient clinic, subjects fitting the clinical eligibility 
criteria will be invited back for a formal trial enrolment visit in the Centre‟s Clinical 
Research Unit. 
If the patient wishes to start steroids at their first hospital appointment, or there is any 
clinical urgency and: 
 They want to take part in the trial, they will be enrolled at this first visit 
 They are unclear whether or not they wish to take part in the trial, or it is 
impractical / inconvenient for them to complete the trial enrolment 
assessments (including questionnaires, tear and blood tests) at this visit, 
they will start the steroid treatment protocol (which is standard whether or 
not the patient takes part in the study). Their next appointment will then be 
arranged 2 weeks later in the Trial Centre‟s Clinical Research Unit, at 
which time they can be simultaneously enrolled and randomised should 
they wish to take part in the study. 
 
Enrolment Visit  
Purpose: to confirm eligibility, further discuss the pros and cons of taking part in the 
study, conduct the trial baseline assessments and obtain consent if the patient 
wishes to take part 
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A modified version of the Initial Assessment Proforma (Appendix 2) published in 
2002 by the European Group on Graves Orbitopathy (EUGOGO) will be used for 
recording the case history and examination features of each potential Trial Subject. 
The key components of the screening visit are: 
 
Consultation 
To document the: 
 Duration and severity of TED symptoms 
 TED treatment to date 
 Prior and current thyroid status and treatments 
 Ocular Co-morbidity 
 General Past Medical History 
 Current medications 
 Smoking History 
 
Ocular Examination 
This will be conducted according to the trial‟s standard operating procedures 
to assess: 
 Snellen Visual Acuity 
 Eyelid redness and swelling 
 Conjunctival redness and chemosis 
 Caruncular swelling 
 Palpebral aperture 
 Corneal integrity 
 Proptosis (using an Oculus © exophthalmometer) 
 Oculomotility, including 
 Monocular Ductions in six directions of gaze53 
 Gorman‟s Diplopia score54 
 Intraocular pressure in primary position and upgaze 
o Optic Nerve Function, including 
 Colour Vision (Ishihara assessment) 
 Relative Afferent Pupillary Defect 
 Visual Fields 
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 Optic disc assessment 
 
General Examination 
 Weight / height 
 Blood Pressure  
 Urinalysis 
 
Investigation results review 
 Blood tests: 
o Full Blood Count (FBC) 
o Thyroid Function Tests (TSH, FT3, FT4) 
o Liver Function Tests (LFTs) 
o Urea, Creatinine and Electrolytes (U&Es) 
o Random Glucose (Glu) 
o Thiopurine methyltransferase (TPMT) Activity 
Enrolment 
Eligible subjects who have received and read the Patient Information Sheet 
prior to their review will be asked to enrol and start the standard oral steroid 
treatment regime.  
5.3 Withdrawal 
5.3.1 Exit Criteria 
AT ANY TIME  
 Development of Dysthryroid-associated Optic Neuropathy (DON), defined as  
EITHER 
 a significant visual field defect  
 a relative afferent pupilary defect 
OR 
 an unexplainable best corrected visual acuity of less than 6/12 (with or 
without a swollen optic disc) 
 Patient withdrawal of consent 
BEFORE RANDOMISATION 
Non-response to Steroids 
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 Trial subjects who have had TED for more than 6 months and whose Clinical 
Activity Score (CAS) has not improved by at least one point 2 weeks after 
starting high-dose steroids, are unlikely to benefit from Radiotherapy and / or 
Azathioprine. They will be withdrawn from the trial – ie they will not be 
randomised. 
AFTER RANDOMISATION 
Worsening TED severity 
 Increasing Clinical Activity Score (CAS) by ≥2 points, confirmed on repeat 
examination (within 14 days). 
Azathioprine toxicity  
(Full blood count & liver function tests will be measured every week for the first 4 
weeks and then 8 weekly until completion of trial) 
 Fall in any of the following measures below the local laboratory‟s 
reference range: 
o Total White Cell Count 
o Neutrophil Count 
 A persistent fall in lymphocyte count to < 0.5 x 109 / L despite a reduction 
in azathioprine dose (see section 6.1.3 – oral azathioprine treatment 
protocol) 
 A persistent Alanine Aminotransferase (ALT) rise to >120 IU/L (ie >3x the 
upper limit of normal) despite a reduction in azathioprine dose (see 
section  6.1.3 - oral azathioprine treatment protocol)  
 A persistent Alkaline Phosphatase (ALP) rise to  > 360 IU / L (ie >3x the 
upper limit of normal) despite a reduction in azathioprine dose (see 
section  6.1.3 - oral azathioprine treatment protocol) 
 A rise in bilirubin to > 40 µmol / L 
 Any other adverse event necessitating withdrawal of azathioprine, eg 
patient intolerance (eg lethargy and nausea) or pancreatitis. 
Other 
 A Serious Adverse Event potentially attributable to radiotherapy or 
azathioprine. 
5.3.2 Treatment of Withdrawn Subjects 
The patient, Consultant Ophthalmologist and Consultant Radiotherapist responsible 
for their care, will be informed of their treatment allocation on withdrawal from the 
trial. If the patient received sham-radiotherapy or placebo tablets (or both) they will 
be offered the active treatments (if appropriate). Withdrawn patients will also have 
access to alternative therapies, such as other immunosuppressive agents or surgery. 
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5.3.3 Follow-up of Withdrawn Subjects 
Care for withdrawn subjects will return to their referring ophthalmologist, however 
they will also be invited to attend assessment visits at 3, 12 and 36 months, to obtain 
outcome data in accordance with the planned intention-to-treat analysis. 
5.3.4 Management of Data from Withdrawn Subjects 
All withdrawn patients will be invited to produce outcome data for the purposes of the 
planned intention-to-treat analysis (see 5.3.3). Withdrawn patients who have no 
outcome data will have data imputed using the principle of last observation carried 
forward. They will not be „replaced‟.  
 
6 TRIAL TREATMENTS 
6.1 Trial Interventions 
6.1.1 Radiotherapy Protocols 
 
ST BARTHOLOMEW’S HOSPITAL (LONDON), THE CHRISTIE 
HOSPITAL (MANCHESTER), AND THE BEATSON ONCOLOGY 
CENTRE (GLASGOW) 
 
1. Planning 
 
 Orbital CT scan  
 The lens, orbit and pituitary are outlined. The post orbital cone should 
be encompassed by the 95% isodose and the maximum dose to the 
lens is < 10%. A dosimetric plan is produced and “signed off” by the 
appropriate Clinical Oncologist. 
 The plan is verified prior to starting treatment  
 
2. Immobilisation 
 
 Full head shell (individually made for each patient) 
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3. Treatment 
 
 Prior to starting treatment appropriate data checks are completed  
 Field Arrangement 
Generally a 5 x 5cm lateral field planned to lens and orbit position 
(fields may not be truly opposed if lens dose > 10%) 
 Dose 
 20 Gy to the retrobulbar orbit 
 Fractionation 
 12 Fractions over 2.5 – 3 weeks 
 
BRISTOL ONCOLOGY CENTRE 
 
1. Planning 
 
 The patient is marked up on the treatment machine.   
 
 The patient lies supine with an appropriate firm head-rest such that 
the outer canthus and the tragus lie on a vertical line.   The distance 
from chin to the supra-sternal notch is measured and recorded 
 
2. Immobilisation 
 
 SP12 with tape across the forehead 
 
3. Apparatus 
 
 6-MV linear accelerator 
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4. Treatment 
 Isodose Planning & Verification 
Isodose plans are not produced as a routine.  Electronic portal imaging 
devices (EPIDs) will be used on both fields on day 1, and checked by the 
Clinical Oncologist 
 Field Arrangement 
4cm x 4cm lateral opposed fields (using asymmetric jaws to eliminate 
divergence towards the contra-lateral lens) 
 Setting-up Details 
o Lasers are used to ensure symmetry as follows: 
 Lt → Rt. = Patient midline 
 Sup → Inf. = Through outer canthus 
o The patient is planned using a 6 cm wide field with the asymmetric 
jaws set as below: 
 Post independent Jaw = 4cm 
 Ant independent Jaw = 2cm 
 Gantry = 90º 
 Diaphragm = 90º 
o The light beam is set to just skim the surface of the ipsi-lateral 
cornea, by adjusting the couch height as necessary. The post "T" 
junction and centre (point A) are marked with felt tip pen. 
o The gantry is rotated to 270º, and the diaphragm to 270º. Minor 
adjustments are made to the patient's head and the couch 
positioned to ensure the light beam just skims the surface of the 
cornea on this side whilst keeping the first centre correct.  The 
post "T" junction and centre (point A) are marked with felt tip pen 
as before. 
o The head is taped, and the alignment of the marks is checked 
o The separation is measured at the field centre 
o The anterior independent jaw is set to zero 
 Dose  
 20 Gy to the retro-bulbar orbit (prescribed as mid-plane dose) 
 
 Fractionation 
 12 Fractions over 2.5 weeks 
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Although Barts and Bristol Oncology Centre have different planning, 
immobilisation and treatment protocols (and differences in apparatus mean that 
this cannot be standardised), the dose, fractionation and field orientation is 
essentially identical in each Centre. 
 
6.1.2 Sham-radiotherapy Protocols 
 
ST BARTHOLOMEW’S HOSPITAL (LONDON), THE CHRISTIE 
HOSPITAL (MANCHESTER), AND THE BEATSON ONCOLOGY 
CENTRE (GLASGOW) 
1. Planning, Immobilisation and Apparatus 
 
 Patients in the sham-radiotherapy arm of the study will also have a 
sham planning CT scan, so that they are not exposed to any ionising 
radiation. 
 Otherwise their planning will be the same as for „radiotherapy‟ except a 
generic dosimetric plan will be used as no megavoltage dose is to be 
received, with downloaded monitor units equal to 0. 
 
2. Treatment 
 
 As for „radiotherapy‟ except the dose will be zero Gy because the 
apparatus will not be turned on. Instead, a noise-emitting electronic 
device will be placed above the gantry of the machine and the 
patient will hear a similar sound to that which accompanies normal 
treatment.  
 
BRISTOL ONCOLOGY CENTRE 
1. Planning, Immobilisation and Apparatus 
 
 As for  „radiotherapy‟  
(NB There is no ionising radiation exposure in planning) 
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2. Treatment 
 
 As for „radiotherapy‟ except the dose will be zero Gy because the 
apparatus will not be turned on. Instead, a noise-emitting electronic 
device will be placed above the gantry of the machine and the 
patient will hear a similar sound to that which accompanies normal 
treatment.  
 
Any patients starting radiotherapy more than 9 weeks after randomisation will be 
considered to be outside the protocol, and therefore will not be allowed to proceed 
with trial treatment.  
 
6.1.3 Oral Azathioprine Treatment Protocol 
AZATHIOPRINE STARTING DOSE (2-3mg / kg): 
 
 
BODY MASS 
 
AZATHIOPRINE 
STARTING DOSE 
(Once Daily) 
NUMBER OF 
AZATHIOPRINE 50mg 
TABLETS (per day) 
 
< 50 kg 
 
100 mg 2 
 
50 – 79kg 
 
150 mg 3 
 
≥ 80 kg 
 
200 mg 4 
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MONITORING FOR ADVERSE EVENTS 
 
 Full Blood Count (FBC) weekly for the first 4 weeks of treatment, then every 8 
weeks 
 Liver Function Tests (LFTs) at week 4, then every 8 weeks. 
 
DOSE ADJUSTMENT IN RESPONSE TO LFT CHANGE 
 
Alanine aminotransferase (ALT) 
1. If ALT >120 IU/L (ie >3x the upper limit of normal), repeat in 2 weeks and see 
if upwards or downwards trend 
2. If repeat ALT 2 weeks later is ≤ the last value: 
a. Continue treatment and do not change Azathioprine dose. 
b. Re-check ALT in 8 weeks 
 If this is: 
i. <120 IU/L: continue at same dose and repeat LFT in 8 weeks 
(when return to 1) 
ii. ≥120 IU/L: Go straight back to 1 
3. If repeat ALT 2 weeks later is > the last value: 
a. Reduce Azathioprine dose by 50mg/day 
b. Re-check LFTs in 2 weeks 
If repeat ALT 2 weeks after this dose change is ≤ the last value: 
i. Continue treatment at the reduced dose. 
ii. Re-check LFTs in 8 weeks (when return to 1) 
If repeat ALT 2 weeks after this dose change is > the last value: 
iii. Stop azathioprine and exit the trial 
4. If ALT >275IU/L at any point, stop azathioprine and exit the trial 
5. If ALT ≥120 when returning to 1 for a second time, discuss with unmasked 
investigator  
 
Alkaline Phosphatase (ALP) 
6. If ALP > 360 IU/L (ie >3x the upper limit of normal), repeat in 2 weeks and 
see if upwards or downwards trend 
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7. If repeat ALP 2 weeks later is ≤ the last value: 
a. Continue treatment and do not change Azathioprine dose 
b. Re-check ALP in 8 weeks 
 If this is: 
i. <360 IU/L: continue at same dose and repeat LFT in 8 weeks 
(when return to 6) 
ii. ≥360 IU/L: Go straight back to 6 
8. If repeat ALP 2 weeks later is > the last value: 
c. Reduce Azathioprine dose by 50mg/day. 
d. Re-check LFTs in 2 weeks 
If repeat ALP 2 weeks after this dose change is ≤ the last value: 
i. Continue treatment at the reduced dose 
ii. Re-check LFTs in 8 weeks (when return to 6) 
If repeat ALP 2 weeks after this dose change is > the last value: 
iii. Stop azathioprine and exit the trial 
9. If ALP >630 IU/L at any point, stop azathioprine and exit the trial 
10. If ALP > 360 IU/L when returning to 6 for a second time, discuss with 
unmasked investigator. 
 
Bilirubin 
11. If bilirubin > 40 µmol/L, stop azathioprine and exit the trial 
 
DOSE ADJUSTMENT IN RESPONSE TO LYMPHOPENIA 
12. If lymphocyte count <0.5x109/L reduce azathioprine dose by 50mg/day and 
repeat FBC in 2 weeks 
13. If repeat lymphocyte count >0.5x109/L 
a. Repeat FBC in 2 weeks 
i. If repeat lymphocyte count remains >0.5x109/L continue 
treatment at reduced dose and repeat FBC in 8 weeks (when 
return to 12) 
ii. If repeat lymphocyte count <0.5x109/L, stop azathioprine and 
exit the trial 
14. If repeat lymphocyte count <0.5x 09/L, stop azathioprine and exit the trial  
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15. If repeat lymphocyte count <0.5x109/L when returning to 12 for a second time, 
discuss with unmasked investigator  
 
AZATHIOPRINE TREATMENT ALGORITHM 
Full Blood Count (FBC) every week for 4 weeks and then every 8 weeks
Liver Function Tests (LFT) at week 4 and then every 8 weeks
Alanine Transferase
(ALT)
If >275IU/L at any point STOP 
AZATHIOPRINE & EXIT TRIAL
If ALT ≥ 120 IU/L  (ie ≥3x the 
upper limit of normal) repeat 
LFT in 2 weeks *
DECREASED OR 
SAME
Continue treatment 
at same dose
Repeat LFT in 8 
weeks
If repeat ALT < 120 
IU/L
Continue same dose 
and repeat LFT in 8 
weeks (when return 
to #)
If repeat ALT ≥120 
IU/L go straight back 
to #
INCREASED
Reduce azathioprine 
dose by 50mg/day
Repeat LFT in 2 weeks
DECREASED 
OR SAME
Continue 
treatment at 
reduced dose
Repeat LFT 
in 8 weeks 
(when return 
to #)
INCREASED
STOP 
AZATHIOPRINE 
& EXIT TRIAL
Bilirubin
If bilirubin > 40 mol/L 
at any point STOP 
AZATHIOPRINE & EXIT 
TRIAL
Alkaline phosphtatase
(ALP)
If >630IU/L at any point STOP 
AZATHIOPRINE & EXIT TRIAL
If ALP ≥ 360 IU/L (ie ≥3x 
the upper limit of normal) 
repeat LFT in 2 weeks*
DECREASED OR 
SAME
Continue treatment 
at same dose
Repeat LFT in 8 
weeks
If repeat ALP 
< 360 IU/L 
Continue 
same dose 
and repeat 
LFT in 8 
weeks (when 
return to †)
If repeat ALP 
≥ 360 IU/L go 
straight back 
to †
INCREASED
Reduce dose of 
azathioprine by 
50mg/day
Repeat LFT in 2 
weeks
DECREASED 
OR SAME
Continue 
treatment at 
reduced dose
Repeat LFT 
in 8 weeks 
(when return 
to †)
INCREASED
STOP 
AZATHIOPRINE & 
EXIT TRIAL
If lymphocyte count 
<0.5x109/L reduce 
azathioprine dose by 
50mg/day*
Repeat FBC in 2 weeks
†#
If repeat 
lymphocyte 
count 
>0.5x109/L 
repeat FBC in 
2 weeks
If repeat 
lymphocyte count 
<0.5 X 109/L
STOP 
AZATHIOPRINE & 
EXIT TRIAL
If repeat lymphocyte 
count remains 
≥0.5x109/L, continue 
treatment at reduced 
dose and repeat 
FBC in 8 weeks 
(when return to §)
If Total White Cell Count or 
Neutrophil Count are at any 
point below the local 
laboratory’s reference range
STOP AZATHIOPRINE & 
EXIT TRIAL
§
*If 2nd time discuss with unmasked investigator
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6.1.4 Placebo 
 
PLACEBO STARTING ‘DOSE’ 
 
 
BODY MASS 
 
NUMBER OF PLACEBO 
TABLETS (per day) 
 
< 50 kg 
 
2 
 
50 – 79kg 
 
3 
 
≥ 80 kg 
 
4 
 
Hence the number of placebo tablets matches the number of Azathioprine (50mg) 
tablets given to a patient of equivalent body mass in the active treatment group. 
 
BLOOD MONITORING AND TABLET NUMBER ADJUSTMENT 
Patients randomised to receive placebo tablets will have the same blood tests as the 
azathioprine treated group. 
≤5% of the placebo treated group will be randomly selected and recalled for repeat 
blood tests (to match the management of azathioprine treated patients). The number 
of placebo tablets given to these trial subjects will also vary (to mimic the 
azathioprine dose titration)   
 
6.2 Standardised Treatments (Common to all trial arms) 
On enrolment all patients will receive a standard combination of oral steroid, 
bisphosphonate and proton-pump inhibitor (PPI) treatment. 
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6.2.1 Oral Prednisolone 
Non-enteric coated preparations will be used unless the patient suffers indigestion 
with this form of medication despite PPI therapy. All patients will receive a course of 
prednisolone according to the protocol below. 
 
TIME AFTER 
ENROLMENT 
PREDNISOLONE DOSE 
(mg per day) 
1 – 3 days 80 
4 – 7 days 60 
2nd week 40 
3 – 6 weeks 30 
7 – 10 weeks 20 
11 – 14 weeks 15 
15 – 18 weeks 10 
19 – 20 weeks 7.5 
21 – 22 weeks 5 
23 – 24 weeks 2.5 
 
NB Intravenous methyl-prednisolone will not be used (to maximise recruitment of 
patients from a wide geographical area around the Trial Centres and facilitate their 
management on an outpatient basis). 
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6.2.2 Treatments to prevent steroid-associated side-effects 
 
 Bisphosphonates 
Either: 
o Risedronate Sodium (Actonel®) 35mg po once weekly 
Or 
o Alendroic Acid (Fosamax®) 70mg po once weekly 
  
 To continue for the duration of oral prednisolone treatment 
 
 Proton pump inhibitors: 
To be prescribed if patients have a previous history of upper-gastrointestinal 
inflammation (with or without steroid use), or report indigestion on taking oral 
prednisolone.  
 
Either: 
o Lansoprazole (Zoton®) 15mg po OD (for prophylaxis), or 30mg po OD 
(if symptomatic) 
Or 
o Omeprazole 10mg po OD (for prophylaxis), or 20mg po OD (if 
symptomatic)  
 
To continue for the duration of oral prednisolone treatment or to use as 
required. 
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6.3 Endocrine Management 
Hyperthyroid Patients will be treated with carbimazole 40mg daily until euthyroid 
and then transferred to block-replace treatment (carbimazole 40mg and thyroxine 
100µg daily).  
Hypothyroid Patients will be treated with thyroxine, and the dose adjusted to 
normalise TSH levels.  
Previously Hyperthyroid Patients (treated in the last 1 year) will also receive block-
replace therapy (as above) to ensure stable thyroid function. 
Previously Hypothyroid Patients will have their dose adjusted (if required) 
according to their TSH levels. 
Euthyroid Patients (5% of patients with TED have normal thyroid hormone levels) 
will not require any treatment for thyroid disease, but their Thyroid Function Tests 
(TSH, FT3, FT4) will be monitored at 3 monthly intervals and treated (as above) if 
changes develop. 
 
ENDOCRINE MANAGEMENT ALGORITHM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TSH, FT4+ FT3
in reference range
No – FT4 low
Or TSH > 4mu/l
Begin or increase dose of 
thyroxine by 50ug
Recheck TSH, FT4,
FT3 in 6 weeks
No but TSH not raised
And FT4/FT3 in
Reference range
Yes
No – TSH suppressed
AND FT3 or FT4 raised
If on no Rx, begin carbimazole1 40mg/day
If on thyroxine, reduce dose by 25-50ug/day
If on carbimazole and thyroxine, 
reduce thyroxine by 25ug/day
If on carbimazole alone2
– increase/ensure dose to/is 40mg
Recheck TSH, FT4,
FT3 in 6 weeks
1If intolerant of carbimazole or on PTU, discuss with trial endocrinologist
2If this has already been done once, and patient remains thyrotoxic, discuss with trial endocrinologist
NB IF ON CARBIMAZOLE AND PT DEVELOPS SORES IN MOUTH WITHOLD MEDICATION
+ CHECK WCC within 24 hours – IF NEUTS< 1.0 discuss with trial endocrinologist within 24 hours
Recheck TSH, FT4,
FT3 in 3 months
If on thyroxine or no treatment - No change in
endocrine treatment
If on carbimazole alone, ensure dose is 40mg 
and add thyroxine 100ug/day
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6.3.1 Responsibility for Endocrine Care 
Patients will either transfer responsibility for their Endocrine care to the trial team 
(under the supervision of the Endocrine Chief Investigator) for the duration of their 
participation in the study, or if they prefer to remain under the care of their own 
Endocrinologist the trial team will liase closely with them in order to ensure that the 
patient is rendered euthyroid and maintained euthyroid for the duration of the trial.  
6.4 Smoking advice 
All trial subjects will be advised to stop smoking. We will monitor changes in smoking 
habits. 
7 ASSESSMENT OF TREATMENT EFFICACY 
Trial subjects will be seen 2 weeks after enrolment to determine their response to, 
and tolerability of, steroids. If they have had TED for more than 6 months and their 
Clinical Activity Score (CAS) has not improved in at least one point at this 2 week 
visit, they are unlikely to benefit from Radiotherapy and / or Azathioprine. 
Consequently they will be withdrawn from the trial and will not be randomised.  
All recruits who either have had TED for less than 6 months, or have improved in at 
least one CAS item in response to steroids, will be randomised to receive either 
radiotherapy, azathioprine or their placebos at their visit 2 weeks post enrolment. 
They will be reviewed again four weeks later to ensure that their TED is not flaring up 
on steroid taper and that they are tolerating Azathioprine before starting radiotherapy; 
then again 6 weeks later for the short-term outcome assessment (about 5 weeks 
after completing radiotherapy), and subsequently every 3 months until the trial exit 
assessment at 1 year (with an optional long-term follow-up assessment at 3 years). 
7.1 Standard Clinical Assessments at each Follow-up Visit 
The primary outcome measures for the trial are based on Clinical Measures of TED 
Severity and Activity. These will be assessed by the Clinical Investigators at each 
follow-up visit and their measurement recorded on the trial‟s Clinical Report Form.  
The key components of the follow-up visits are: 
Consultation 
To establish: 
 Changes in the activity and severity of TED symptoms  
 
 To record: 
 Changes in medications (including thyroid treatments) 
 Changes in smoking habit 
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 Adverse events 
 
Ocular Examination 
This will be conducted by the Clinical Investigators and Hospital Orthoptists 
(+/-  Clinical Research Nurses) to assess: 
 
 Snellen Visual Acuity 
 Eyelid redness and swelling 
 Conjunctival redness and chemosis 
 Caruncular swelling 
 Palpebral aperture 
 Corneal integrity 
 Proptosis (using an Oculus © exophthalmometer) 
 Oculomotility, including 
 Monocular Ductions in six directions of gaze53 
 Gorman‟s Diplopia score54 
 Intraocular pressure in primary position and upgaze 
o Optic Nerve Function, including 
 Colour Vision (Ishihara assessment) 
 Relative Afferent Pupillary Defect 
 Visual Fields 
 Optic disc assessment 
 
General Examination 
 Weight / height 
 Blood Pressure   
 Urinalysis 
 
Investigations 
 Blood tests: 
o Thyroid Function Tests (TSH, FT4 & FT3) 6 – 12 weekly (see 
flow chart in 6.3) 
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Trial subjects will also have blood tests performed by their General 
Practitioner or the Trial Centre (whichever is more convenient) every week for 
4 weeks post randomisation and 2-monthly thereafter (see section 6.1.3) to 
monitor their tolerance of azathioprine. 
7.2 Patient-Centred Measures of Psychosocial Distress, 
Disease Severity and Treatment Efficacy 
It is widely acknowledged that psychological issues related to appearance have 
particular importance in TED55 56, however the implications of this in terms of anxiety, 
social avoidance and depression are poorly understood. This assessment seeks to 
investigate these issues and to evaluate patient‟s perceptions of their visual function 
and appearance in the analysis of treatment efficacy50 
Plan of Investigation 
All trial subjects will be asked to complete 2 standardised psychosocial measures at 
recruitment, 3 months and 1yr (trial end):  
 Hospital Anxiety and Depression Scale (HADS)57 
 Derriford Appearance Scale-Short Form58 measuring appearance-related 
concerns and social avoidance. 
 WHOQoL-Brief Quality of Life Assessment Score 
These have been chosen on the basis of a review of the literature to identify the 
psychological factors most commonly implicated in appearance-related distress59, 
their suitability in the assessment of psychosocial need in people with disfiguring 
conditions60, and for their ease of completion in a clinic setting. 
In addition trial recruits will be asked to complete an English-language version of the 
recently developed Graves‟ Ophthalmopathy Quality of Life (GO-QoL) questionnaire; 
a disease-specific health-related QoL measure61. 
Recruits will also be asked if they are willing to participate in semi-structured 
interviews. Of those who are, a subset of patients (ensuring proportional 
representation of age, gender, trial treatment and trial centre) will be selected for 
interview on the basis their response to the baseline questionnaires (targeting those 
with high and low levels of distress). The interviews will explore their individual 
concerns, strengths and difficulties in social functioning, coping strategies, levels of 
perceived support and the personal financial consequences of their disease. 
Interviews will be either face-to-face or conducted over the telephone. They will be 
tape recorded and subsequently transcribed, after which the tapes will be erased. 
Transcriptions will also be destroyed at the end of the study. 
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7.3 Health Economic Evaluation 
The primary intention of the economic evaluation is to compare the costs and 
benefits of: (i) radiotherapy; and (ii) azathioprine; versus placebo in treating trial 
subjects. 
The different methods of patient care will be evaluated from the viewpoint of the 
National Health Service (NHS) and patients/carers. We will also attempt to estimate 
the societal effect of time off work due to TED. 
1. Measurement of health outcomes 
Evidence for the effectiveness of the different treatments will be collected through the 
trial‟s clinical and psychosocial assessments. Costs will be related to the percentage 
of patients responding to treatment, using the binary long-term primary clinical 
outcome measure. Incremental cost effectiveness ratios will be formed, which will 
estimate the extra cost per extra patient responding to (i) radiotherapy; and (ii) dual-
therapy at 11 months.  
2. Identification of relevant costs / resource use 
The cost of monotherapy and dual-therapy with and without radiotherapy will be 
compared from the point at which patients are randomised, and will include all 
relevant resources under the control of the NHS, all out-of-pocket expenses incurred 
by patients and carers, and time off work due to thyroid eye disease.  
The costs to the NHS identified as being of relevance in the analysis are: 
 Primary care consultations: General Practitioner (face-to-face) General 
Practitioner (telephone), Practice Nurse/Nurse Practitioner, Out-of-Hours 
telephone consultation, Out-of-Hours face-to-face consultation, Home visits. 
 Walk-in Centre 
 NHS Direct 
 Secondary care contacts:  
- Out-patient visits, including routine patient monitoring of TED, which 
involves a complex series of eye movement tests performed by orthoptists 
and involving specialist equipment. These assessments can take up to 45 
mins to perform and patients will also be photographed to obtain an 
objective record of their appearance. As TED can be severely disfiguring 
these appointments may also involve a specialist nurse or counsellor. 
- Treatment costs including the cost of radiotherapy and blood tests, and 
radiological investigations. 
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- Out-patient visits at an endocrinology clinic to monitor and treat the 
underlying thyroid disease 
- Accident & Emergency visits 
- Inpatient stays, including surgical intervention. Patients with increased 
severity of disease may require „emergency‟ surgery to prevent optic nerve 
compression and others may require rehabilitative surgery.  
 Prescribed medication. This will include medication to treat TED and also the 
underlying thyroid disease.  
 The cost of prisms. Patients with double vision require prisms to be fitted to their 
glasses; this may be done by an orthoptist or an optometrist.  
 
The costs to the patients and carers will include: 
 Travel costs incurred during visits to health care facilities 
 Use of over-the-counter drugs, for example lubricating eye drops and oral 
analgesics 
 Prescription charges  
 Expenditure on complementary and alternative therapy, counselling, and support 
groups, plus associated travel costs 
 The cost of glasses / sunglasses 
 Cosmetic-related purchases, for example, make-up  
 Expenditure on smoking 
 Cost of child care and care of other dependents 
 Loss of earnings 
 
The costs to society will include: 
 Time off work 
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3. Measurement of resource use (data collection) 
Data on resource use associated with the interventions will be collected during the 
study by patients in their Trial Diary.  
Information collected from the diary will include: 
 Number of visits, where they took place, who seen, and treatment provided for: 
- Intervention treatment 
- Routine monitoring and treatment of TED 
- Routine monitoring and treatment of underlying thyroid disease 
- Primary and secondary non-routine health care relating to TED and 
underlying thyroid disease  
 Prescribed medication: name of preparation, strength, dosage form, quantity 
 Use of: 
- Out-of-Hours care 
- Walk-in Centre 
- NHS Direct 
 Travel costs for all health care visits: mode of travel and distance, fares paid and 
car parking charges 
 Over-the-counter medication purchased and cost 
 Cost of complementary and alternative medication and associated travel costs 
 Cost of counselling and/or support group, and associated travel costs 
 Cost of glasses, sunglasses, and any cosmetic-related purchases 
 Expenditure on smoking 
 Cost of childcare and care of other dependants 
 Loss of earnings 
 Time off work and employment details 
 
4. Valuation of resource use 
National data sets such as the Unit Costs of Health and Social Care 
(http://www.kent.ac.uk/PSSRU/) will be used to value primary care contacts. 
 
Visits to Walk-in Centres and calls to NHS Direct will be valued using information in 
the National Evaluations 
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(http://www.epi.bris.ac.uk/wic/pdf/WIC%20Evaluation%20Report%20-%20Final.pdf 
and http://www.shef.ac.uk/scharr/mcru/reports/nhsd3.pdf) 
 
The British National Formulary (http://bnf.vhn.net/bnf) will be used to value 
prescribed medication. 
 
Secondary care use will be valued using the Department of Health National 
Reference Costs (http://www.doh.gov.uk/nhsexec/refcosts.htm). 
 
5. Discounting 
Costs and outcomes will not be discounted, as the study will be limited to a period of 
12 months. 
 
6. Uncertainty 
Sensitivity analysis will be conducted in areas where there is uncertainty around 
assumptions about resource use measurement and/or valuation.   
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7.4 Outcome Measures 
7.4.1 Primary 
7.4.1.1 Binary Composite Clinical Outcome Measure 
Response to treatment will be compared between treatment groups 12 months after 
enrolment (11 months after randomisation). This will be determined using a system of 
major and minor criteria modified from others10 16 19. Each component of the 
composite score will be assessed according to the trial‟s Standard Operating 
Procedures. 
Major Criteria 
 An improvement of ≥ 1 grade in diplopia score54  
 An improvement of >8o  of eye movement in any direction53 
 A reduction of ≥ 2 mm in proptosis 
Minor Criteria  
 A reduction of ≥ 2 mm in lid aperture 
 An improvement of ≥ 1 grade in soft tissue involvement46. 
 An improvement in best-corrected visual acuity of ≥ 1 line on the Snellen 
chart.  
 Subjective improvement10 
Response to Treatment 
Very good:  ≥ 2 major criteria 
Good:   1 major criterion 
Fair:   ≥ 2 minor criteria 
No Change:  1 minor criterion 
Worse:   Deterioration in at least 1 major or 2 minor criteria.  
Response Rate 
Number of patients with a fair, good or very good response to treatment versus the 
number of patients who have no change or are worse (expressed as a percentage). 
 
 
 
 
 
 
 
Page 54 of 69 
CIRTED Protocol v5.3, 2 June 2011 
 
7.4.1.2 Ophthalmopathy Index 47  
 
Response to treatment will also be compared between treatment groups 12 months 
after enrolment (11 months after randomisation) with the Ophthalmopathy Index. This 
measure of disease severity is calculated by summating the values in the right-hand 
column of the following table. Each component of the Index will be assessed 
according to the trial‟s Standard Operating Procedures. 
 
DEGREE OF INVOLVEMENT 
 
SCORE 
Soft Tissue Inflammation  
 Slight 1 
 Moderate 2 
 Severe 3 
Exophthalmos (mm)  
 16 0.2 
 17 0.4 
 18 0.6 
 19 0.8 
 20 1 
 21 2 
 22 3 
 ≥23 4 
Palpebral Aperture (mm)  
 8 0.15 
 9 0.45 
 10 0.75 
 11 1.05 
 12 1.35 
 13 1.65 
 14 1.95 
 15 2.25 
 16 2.55 
 17 2.85 
 18 3 
Differential IOP (mmHg)  
 1 0.1 
 2 0.2 
 3 0.3 
 4 0.4 
 5 0.5 
 6 0.6 
 7 0.7 
 8 0.8 
 9 0.9 
 10 1.0 
Diplopia  
 Intermittent 1 
 Inconstant 2 
 Constant 3 
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Cornea  
 Initial Lesions 1 
 Ulcers 2 
 Clouding / Perforation 3 
Optic Neuropathy  
 Abnormal VEP 3 
 VA = 0.5 – 0.9 5 
 VA = 0.1 – 0.4 7 
 VA < 0.1 9 
 
 
7.4.2 Co-Primary Outcome Measure 
7.4.2.1 Clinical Activity Score 49 
 
The average change in Clinical Activity Score (CAS) between enrolment and the 
short-term outcome assessment (6 weeks after radiotherapy) will be compared 
between treatment groups. CAS is calculated by assessing the presence or absence 
of each of the following clinical features using the trial‟s Standard Operating 
Procedures. 
1. Pain 
 Pain on eye movement in the last 4 weeks 
 Painful, oppressive feeling on or behind globe in the last 4 weeks 
 
2. Redness 
 Conjunctival redness 
 Eyelid redness 
3. Swelling 
 Chemosis 
 Swollen caruncle 
 Eyelid oedema 
 Increasing proptosis of > 2mm  
 
4. Impaired Function 
 Decreasing visual acuity of > 1 snellen line 
 Decreasing eye movement of ≥ 8o 53 
Each feature = one point. The maximum score is 10 at each follow-up visit and 7 at 
enrolment (because there will be no previous records to determine changing 
measurements of proptosis, visual acuity and eye movements). 
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7.4.3 Secondary  
7.4.3.1 Clinical Measures 
 Total Eye Score (TES) 8 
7.4.3.2 Psychosocial Measures  
The following will be measured to assess psychosocial effects of TED, and to 
compare psychosocial responses across treatment groups. 
 
 Hospital Anxiety and Depression Scale (HADS) score57 
 Derriford Appearance Scale-Short Form score58 
 Graves‟ Ophthalmopathy Quality of Life (GO-QoL) score61 
 WHOQoL-Brief Quality of Life Assessment Score 
 Open-ended responses to interview questions 
7.4.3.3 Health Economic Measures 
The cost of TED and its treatment will be measured from the perspective of: 
 The National Health Service (NHS) 
 The patient 
 Society 
and compared across treatment groups.  
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8 TREATMENT SAFETY 
There is established clinical experience of both trial interventions, and it is unlikely 
that this trial will contribute significantly to published safety data. However, adverse 
events will be monitored, reported in the trial publications and to the Trial Sponsor 
and Medicines and Healthcare products Regulatory Agency (MHRA) if appropriate. 
8.1 Adverse Events 
An adverse event is any untoward medical occurrence in a patient administered a 
pharmaceutical product, without regard to the possibility of a causal relationship. 
These will be recorded for all trial subjects after enrolment. 
8.2 Serious Adverse Events 
Serious adverse events are: 
 Fatal 
 Life-threatening 
 Disabling or incapacitating 
 Hospitalising (or cause prolonged hospitalisation) 
 The cause of a congenital abnormality or birth defect 
If these occur they will be reported to the Trial Sponsor and Medicines and 
Healthcare products Regulatory Agency (MHRA). 
8.3 Prevention of Adverse Events 
The trial exclusion criteria prevent patients especially at risk of developing adverse 
events from participating in the trial. In particular, patients with abnormal thiopurine 
methyltransferase TPMT activity who are likely to develop bone marrow suppression 
(low activity) or hepatotoxicity (high activity) with azathioprine will not be enrolled. 
Also, diabetic patients who are likely to develop complications with high dose steroid 
use and are at increased risk of developing retinopathy with radiotherapy will not take 
part. 
8.4 Eliciting Adverse Events 
All trial subjects will have an enquiry about co-morbidities, medications and new or 
unexpected symptoms at each follow-up visit, as well as an ophthalmic and general 
examination. Blood tests to monitor for azathioprine‟s potential adverse effects will be 
carried out in accordance with published guidance. 
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9 PLANNED ANALYSES 
9.1 Interim 
See sections 4.6.1.1 and 4.6.1.4.  
9.2 Final 
Data analysis will proceed according to CONSORT guidelines for randomised 
controlled trials. The first stage of the analysis will be to use descriptive statistics to 
describe the group of individuals recruited to the trial in relation to those eligible, and 
to investigate comparability of the trial arms at baseline. The primary intention-to-
treat analyses will comprise comparisons between radiotherapy versus sham-
radiotherapy, and azathioprine versus placebo, for each of the two primary outcomes 
at 12 months follow up. Outcomes for patients participating in the optional long-term 
follow-up study will also be compared 3 years post-enrolment. The comparisons will 
be made using appropriate (that is, logistic or linear) multivariable regression models, 
adjusting for minimisation variables, the factorial design, and the value of the 
outcome variable at baseline. Full attention will be paid to the estimates and the 
confidence intervals for these comparisons as well as the p-values. Secondary 
analyses will then be conducted using regression models with further adjustment for 
any prognostic factors that exhibit marked imbalance at baseline. Patients who have 
no outcome data for the primary analyses will have data imputed using last 
observation carried forward. Patients who have become non-compliant for any 
reason will still be invited to produce outcome data such that they can be included in 
the intention to treat analyses. The assumptions required for the regression models 
will be investigated using appropriate diagnostic plots, and actions such as 
transformation of continuous outcome variables taken as necessary. 
 
The co-primary outcome Clinical Activity Score at 3 months follow up and all 
secondary outcomes will be analysed in the same way, using appropriate (linear or 
logistic) regression models depending on the nature of the outcome measure. 
Bonferroni corrections for multiple testing will be considered for the secondary 
outcomes. 
 
Other secondary analyses will involve: (a) investigation of any interaction between 
the two interventions for each of the two primary outcomes; (b) pre-planned sub-
group analyses to ascertain any differential effects of the interventions according to 
steroid use versus no steroid use in the six months prior to enrolment. These 
secondary analyses are readily performed as extensions to the multivariable 
regression models described above, by simply introducing the appropriate interaction 
terms. However, the precision of the estimates of interaction is very likely to be too 
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poor, and high p-values will most likely reflect low power and so cannot be taken as 
evidence for no interactions. 
 
9.2.1.1 Health Economic Indices 
Costs will be related to the percentage of patients responding to treatment. 
Incremental cost effectiveness ratios will be formed, which will estimate the extra cost 
per extra patient responding to (i) radiotherapy; and (ii) azathioprine 11 months after 
randomisation, and (for patients participating in the long-term follow-up study) 3 
years after enrolment.  
A secondary analysis will estimate the cost-of-illness of Thyroid Eye Disease from a 
societal perspective 
10 DATA HANDLING AND RECORD KEEPING 
Source documents produced for this trial will be kept in the patient‟s hospital records 
and source data will be transcribed into trial-specific Clinical Record Forms (CRFs) at 
the end of each patient visit. This will be checked and signed by the Clinical 
Investigators at each Trial Centre. CRF data will then be transferred onto a bespoke 
database prior to data analysis. All electronically stored patient information will be 
anonymised and patients‟ personal information will be stored on a paper record in a 
locked secure location in each Centre‟s Clinical Trial Facilities.  
11 ETHICS 
The trial protocol, consent documentation, patient information sheets, standard 
correspondence with the patient‟s general practitioner and ethics application form 
received a favourable opinion from a UK Main Research Ethics Committee (REC), 
and the appropriate Local RECs prior to starting recruitment at each Centre. 
12 FINANCIAL AND INSURANCE DETAILS 
Support for this trial has been granted by the following charitable bodies: 
 
 The National Eye Research Centre:  
For administrative and clinical research support; Investigational Medicinal Product 
(IMP) Manufacture (placebo tablets) and packaging (placebo and azathioprine 
tablets); and radiotherapy technician time 
 
 Moorfield’s Eye Hospital Special Trustees:  
For Clinical Research Fellow and administrative support. 
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 Medical Research Committee of the Charitable Trusts for the United Bristol 
Hospitals:  
For the psychosocial outcome assessments and ancillary studies conducted in 
collaboration with The Centre for Appearance Research at the University of the 
West of England. 
 
 National Hospital for Neurology and Neurosurgery and Moorfields Special 
Trustees 
For the ancillary Magnetic Resonance Imaging Study on London patients (see 
section 15.5 and Appendix 1). 
 
The University of Bristol has arranged clinical research insurance to cover the legal 
liability of the University for both negligent and non-negligent harm. In addition the 
study doctors hold substantive or honorary NHS contracts, giving them the protection 
of the NHS clinical negligence arrangements. 
Page 61 of 69 
CIRTED Protocol v5.3, 2 June 2011 
 
13 PATIENT INVOLVEMENT 
13.1 Thyroid Eye Disease Charitable Trust (TEDct) 
 
The Endocrine Chief Investigator is chairman of the TEDct, an active national 
organisation with 800 members. The trial was presented and discussed at their 
meeting at Moorfields Eye Hospital on 12 February 2005 and it received strong 
support. Their members are very aware of the varying clinical practices for this 
condition (some had received radiotherapy, others not; some had been on 
immunosuppression, others not) and because of the impact these treatments had on 
their lives they were very keen to see a proper evidence base established to inform 
management guidelines and ensure that future TED sufferers have access to high-
quality, standardized care. Our efforts to integrate endocrine and ophthalmic care 
were also strongly endorsed. A member of the Trust advised on the contents of the 
trial‟s Patient Information Sheets and Introductory Letter.  
14 PUBLICATION POLICY 
The results of this trial will be submitted for publication in a peer-reviewed medical 
journal regardless of whether the outcome is in favour of the trial interventions.  
15 ANCILLARY STUDIES – Project summaries 
Patients will also be invited to participate in the following optional investigations, and 
may continue to do so after trial withdrawal (even if this is precedes randomisation) 
or completion. 
15.1 Tear Cytokines 
New laboratory tests (using flow-cytometric bead arrays) enable the concentrations 
of inflammatory mediators (cytokines) to be measured in micro-litre volumes of fluid 
(such as tears).  
Pilot data suggests that cytokines released in orbital inflammation, such as TED, may 
be present in tears. If so, tear cytokine assays may be used to develop a new clinical 
test to quantify the severity of an individual‟s orbital inflammation and its potential to 
respond to immunosuppressive therapy.  
Tear samples may be taken from both eyes of trial participants at each visit using 
standard clinical techniques. Tear cytokine levels will then be correlated with clinical 
measures of disease severity and response to immunosuppression.  
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15.2 Steroid Sensitivity Assays 
A new laboratory assay is being developed in Bristol to predict and monitor an 
individual‟s response to steroids and other immunosuppressive drugs. This has the 
potential to enable drug treatments to be tested and tailored to an individual before 
they start therapy, which would be of great benefit to patients with TED and other 
inflammatory conditions. 
CIRTED recruits will have a course of high-dose steroids at the start of the trial and 
the clinical response to this treatment will be prospectively documented using 
standardized measures of disease severity. Hence, they are an ideal cohort of 
patients on which to test the predictive power of this new steroid sensitivity assay. 
Separate consent will be taken from patients for this optional study. Two large blood 
samples (50mls each) will be required, one on enrolment and another four weeks 
after starting steroids. 
 
15.3 Azathioprine Metabolite Assays 
There is some evidence that azathioprine metabolite assays can be used to predict 
disease response in patients with inflammatory bowel disease. If this is true for 
patients with TED it would enable an individual‟s drug dose to be titrated to ensure 
that the concentrations of active metabolites in their blood were adequate to achieve 
an optimal disease response. It is currently thought that most patients who fail 
treatment do so because they have an inadequate drug dose, rather than because 
they are resistant to therapy. The purpose of this study (which is being performed in 
collaboration with the Purine Research Laboratory, Guy‟s and St Thomas‟ Hospital, 
London) is to establish whether the concentrations of Azathioprine metabolites in 
CIRTED patients‟ blood correlates with their disease severity and response to 
immunosuppression.  
 
Patients will be asked for a single 5ml blood sample at the short and long-term 
follow-up assessments (3 and 11 months after randomisation). 
 
15.4 Thyroid Stimulating Antibody Levels 
The purpose of this study is to correlate the concentration of Thyroid Stimulating 
Antibodies (using newly available assays) in the serum of CIRTED patients with their 
disease severity and response to treatment.  
 
Patients may be asked for a single small blood sample (5mls) at each follow-up visit. 
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15.5 Magnetic Resonance Imaging (MRI) 
Up to fifty of the patients recruited in London will be invited to participate in this 
ancillary study, the primary goals of which are to validate the use of MRI as a 
measure of orbital inflammation to use in future studies of immunosuppressive 
therapy in Thyroid Eye Disease (TED) and to evaluate the use of a novel MRI 
technique (using Diffusion and Magnetism Sequences) in grading TED severity. Each 
MRI study participant will have up to 3 scans - at trial enrolment, 3 months and 12 
months (see separate MEH / NHNN TED MRI protocol) with the option of 
undertaking repeat images if required. 
 
15.6 Future Studies 
 
A small blood sample (5mls) may be taken at each visit and stored in our laboratories 
for use in future TED research. The exact nature of the tests which will be performed 
on these samples is not known and they will be anonymised so that they will not be 
linked to any patient-identifiable information. This means that trial subjects will never 
be able to find out the results of tests done on these stored samples and the 
investigators will not be able to trace results back to an individual patient. 
 
Anonymised tear samples may also be stored after the end of the trial. 
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16 DIAGRAMATIC TRIAL OVERVIEW 
Pre-enrolment
screening
Recruitment -START ORAL STEROIDS
Randomisation 0 weeks
AZATHIOPRINE AZATHIOPRINE PLACEBO PLACEBO
SHAM -
RADIOTHERAPYRADIOTHERAPY
SHAM -
RADIOTHERAPYRADIOTHERAPY
STOP 
STEROIDS 
AFTER 6 
MONTHS
48 weeks
Follow-up visits @ 12 weekly intervals 
12 weeks
Completion
Optional review 3 years
- 2  weeks
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